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Abstract
Interleukin-1 (IL-1) as a potential contributor to the pathophysiology of Alzheimer's
Disease
By
Sara Nicole Resch
Advisor: Susan D. Croll
Elevations of the pro-inflammatory cytokine interleukin-1 (IL-1) have been reported as part of
the inflammatory response to injury and neurodegenerative disorders. The observation of
increased IL-1 levels in the brains of patients with Alzheimer’s disease (AD) triggered over two
decades of research implicating IL-1 in the disease pathogenesis. IL-1 has been suggested to
modulate a variety of actions related to AD pathology, including the processing of the Aβ
precursor protein and deposition of amyloid plaques. IL-1 also activates glial cells and induces
recruitment of leukocytes and peripheral macrophages to the CNS across the blood-brain barrier
(BBB). When exposed to IL-1, microglia and macrophages take on a classical activation
phenotype resulting in the release of more inflammatory cytokines and reactive oxygen species
that can cause cell degeneration. In addition, IL-1 expression has been shown to impair
hippocampally-mediated memory processes. In fact, imaging studies with AD patients have
demonstrated closer correlations between cognitive function and activated microglia than
between cognitive function and amyloid plaque burden. Epidemiological studies reveal a
reduced risk of developing AD for chronic users of anti-inflammatory drugs, but clinical trials
have not shown a consistent benefit of NSAID treatment. In this study, we attempted a more
targeted approach to anti-inflammation treatment through chronic, systemic administration of the
mIL-1 Trap, which specifically inhibits IL-1 signaling, to transgenic swAPP/PS1 mice. After 5
months of treatment, animals that were treated with the mIL-1 Trap performed significantly
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better on water maze acquisition, a measure of learning, than transgenic animals treated with
mFc (placebo). However, the hippocampal plaque burden (number of plaques, average plaque
size, and proportion of hippocampus covered with plaques) was unchanged by the treatment.
We also found an effect of the mIL-1 Trap treatment on microglial morphology in the
hippocampus. Animals treated with mIL-1 Trap had larger somas for microglia adjacent to
amyloid plaques but smaller somas for microglia that were distant from plaques. Finally,
correlations between the plaque measurements, cognitive performances, and microglial
measurements revealed differences between the two treatment groups. These findings may shed
more light on the relationship between interleukin-1, neuroinflammation, and plaque pathology
in Alzheimer’s disease.
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Chapter 1
INTRODUCTION
Interleukin-1
Interleukin-1 (IL-1) is a protein that is part of a larger family of inflammatory and
regulatory cytokines with especially important roles in regulation of the immune system. IL-1 is
found in two distinct isoforms, IL-1α and IL-1β, although IL-1β is considered the primary active
isoform. They are both synthesized as large precursor proteins by cells in the central nervous
system (CNS) as well as by peripheral cells, such as lymphocytes and monocytes (Allan, Tyrrell,
& Rothwell, 2005). Mature IL-1 is formed by cleavage of its proprotein, Prol-IL-1. Pro-IL-1α is
active on its own, but Pro-IL-1β is biologically inactive and must be cleaved by Caspase-1 or IL1β converting enzyme (ICE) in order to produce the active IL-1β protein (Thornberry &
Molineaux, 1995). Active IL-1β (hereafter simply referred to as IL-1) is a secreted protein that
can be released to induce or augment inflammatory responses throughout the body.
IL-1 exerts its biological actions through the cell surface receptor IL-1R1, which is
expressed in many cells throughout the body, including in the brain where the highest levels are
observed in the pyramidal cell layer of the hippocampus, dentate gyrus, cerebellum, pituitary
gland, and hypothalamus (Farrar, Kilian, Ruff, Hill, & Pert, 1987; Cunningham et al., 1992). IL1 agonists bind to the receptor and cause downstream effects due to association with an
accessory protein. In addition to the IL-1 family agonists, many cells produce IL-1ra, an
endogenous antagonist to IL-1R1 that binds to the receptor but does not trigger the receptor
association with its accessory protein, therefore competitively blocking IL-1 signaling through
IL-1R1 (for reviews see Allan et al., 2005; Patel, Boutin & Allan, 2003).
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IL-1 and the Inflammatory Response
IL-1 is one of the most widely studied inflammatory mediators. In addition to its role in
more traditional immune diseases, it has been implicated in a wide range of acute and chronic
neurodegenerative conditions. IL-1β is an important factor in neuroinflammation, including in
the CNS's response to pathogens, injury and cell death. The innate neuroinflammatory response
is characterized by activation of resident glial cells (microglia and astrocytes), infiltration of
peripheral immune cells (leukocytes), production of the enzyme cyclooxygenase-2 (COX-2), and
the expression of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α (Basu et al., 2002).
IL-1β is primarily produced by microglia, the resident macrophages of the CNS (Van Dam,
Bauer, Tilders, & Berkenbosch, 1995). Microglia respond to pathogen-associated molecular
patterns (PAMPs) through pathogen recognition receptors, such as toll-like receptors (TLR). In
response to a PAMP, the TLR becomes activated and begins gene transcription of caspase-1,
resulting in a surge of IL-1 in the brain (Eriksson et al., 1999).
IL-1 and other cytokines released in the early innate stage of the immune response
activate the later adaptive immune response. The adaptive response involves activation and
recruitment of peripheral leukocytes, including lymphocytes, to the site of the injury (Carpentier
& Palmer, 2009). The pathogens and affected cells are then removed through antigen
presentation and recognition, as well as production of antibodies and effector T and B cells
(Varnum & Ikezu, 2012; Carpentier & Palmer, 2009). IL-1 also activates the hypothalamicpituitary-adrenal axis (HPA axis) to release glucocorticoids, which may act as antiinflammatories and suppress the release of pro-inflammatory proteins (Silverman, Pearce, Biron,
& Miller, 2005). As the initiating PAMPs are cleared, the immune responses are resolved
through a decrease in pro-inflammatory cytokines and an increase in glucocorticoids and anti-
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inflammatory cytokines like IL-4, IL-10 and TGF-β. This negative feedback control prevents an
overactive inflammatory response and restores homeostasis (Silverman et al., 2005).
IL-1 in Acute CNS Injury
In the normal brain, expression of IL-1 is low, but acute CNS injury causes a sharp
increase in IL-1 production. Elevated levels of the cytokine are found in the cerebrospinal fluid
of patients with a range of CNS injuries, including infections, stroke, and traumatic injuries
(Patel et al., 2003; Allan et al., 2005). In rodents, the experimental induction of both ischemia
and excitotoxicity rapidly stimulates an increase in expression of IL-1β protein and mRNA (Liu
et al., 1993; Pearson, Rothwell, & Toulmound, 1999).
There is evidence to suggest that IL-1β plays a causal role in the cell death observed in
CNS injury. The time course of IL-1 expression provides indirect evidence. For example,
stroke, head injury and ischemia are acute events, but cell degeneration can occur hours to days
after the initial injury, corresponding to the release of IL-1β and other pro-inflammatory
cytokines (Allan & Rothwell, 2001). Though IL-1β by itself does not cause cell death, it
contributes to neurodegeneration. When IL-1β is injected along with experimental induction of
ischemia, it markedly increases cell damage (Loddick & Rothwell, 1996; Stroemer & Rothwell,
1998). Acute increases of IL-1β can exacerbate excitotoxicity induced by NMDA receptor
agonists, partly by stimulating glial production of nitric oxide (Morimoto, Murasugi, & Oda,
2002). Further evidence comes from the inhibition of IL-1 during CNS injury, which has
protective effects. Blocking IL-1 through the injection of IL-1ra (Loddick & Rothwell, 1996;
Stroemer & Rothwell, 1997) or an ICE inhibitor (Loddick, MacKenzie, & Rothwell, 1996)
reduces cell death associated with ischemia and traumatic brain injury in rodents.
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IL-1 in Infection
IL-1 and other pro-inflammatory cytokines play a key role in the immune response to
infection. IL-1 is involved in producing symptoms of infection, such as fever and hyperalgesia
and behavioral changes including lethargy, anorexia, and decreased activity (Kelley et al., 2003).
These symptoms, called “sickness behavior” are part of a motivational state in which behavior is
organized to optimize fighting off the infection. Fever, an increase in the regular set point of
body temperature, causes the organism to seek warmer temperatures and reduce heat loss,
inhibiting the growth of pathogens. Since the metabolic cost of fever is high, lethargy forces the
individual to rest and conserve energy for fighting the pathogen (Dantzer, 2001).
Infection is often experimentally induced through administration of Lipopolysaccharide
(LPS), a component of Gram-negative bacteria, which increases expression of IL-1α and IL-1β
in the brain (van Dam et al., 1998). Injections of LPS or cytokines into either the periphery or
the lateral ventricle of the brain results in decreased locomotor activity, reduced food intake, and
reduced grooming (Kent et al., 1992). Intracerebroventricular (ICV) pretreatment with IL-1
receptor antagonist blocks some behavioral symptoms of either ICV or peripheral injection with
IL-1β (Bluthe, Dantzer, & Kelley, 1992). Aged mice show prolonged and exaggerated sickness
behavior in response to LPS, corresponding to greater increases of pro-inflammatory cytokines
and microglial activation markers (Huang, Henry, Dantzer, Johnson, & Godbout, 2008).
It is important to note that CNS production of IL-1 occurs even in response to infections
in the periphery. Intraperitoneal injections of LPS induce the expression of the pro-inflammatory
cytokines IL-1 and TNF-α followed later by IL-6 and IL-1ra in the brain (Laye, Parnet, Goujon,
& Dantzer, 1994). The finding that ICV IL-1ra inhibits sickness behavior induced by peripheral
IL-1 suggests that the symptoms of peripheral infection are probably centrally mediated (Bluthe
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et al., 1992). Peripheral LPS or IL-1β stimulates the vagus nerve, leading to activation in the
nerve’s primary and secondary projection areas and activation of the HPA axis (Dantzer, 2001).
In addition to this fast neural pathway, IL-1β signals the brain via a slower humoral pathway.
IL-1β production in the brain first occurs in circumventricular organs, such as the area postrema,
and then spreads into the rest of the brain. The IL-1β then activates parenchymal structures,
recruits microglia and induces expression of iNOS (Konsman, Kelley, & Dantzer, 1999).
Alzheimer’s Disease
IL-1-mediated neuroinflammation has been implicated in the pathogenesis of several
neurodegenerative diseases, including Alzheimer’s disease (AD). AD is the most common form
of dementia and it presents with progressive decline of cognitive functioning in elderly
populations. Symptoms of AD have an insidious onset over the course of months or years and
progressively worsen. The most commonly affected cognitive domain is memory, with a
progressive inability to learn and recall new information, but other cognitive functions can also
be affected, such as language and executive functioning (McKhann et al., 2011).
Neuropsychiatric symptoms are prevalent in patients suffering from the disease. Of these
symptoms, depression and anxiety are particularly common (Di Iulio et al., 2010), along with
agitation (Porter et al., 2003; Mega, Cummings, Fiorello, & Gornbein, 1996).
The characteristic pathology of AD is the intraneuronal accumulation of
hyperphosphorylated tau and extracellular deposits of Aβ in the form of amyloid plaques
(Alzheimer et al., 1995; Dickson et al., 1988). AD also is associated with a loss of neurons and
synapses, leading to atrophy especially in the frontal and temporal cortices (Davies, Mann,
Sumpter, & Yates, 1987). Neurotransmitter levels and function are also altered in AD, with
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cholinergic function being one of the earliest and most severely impacted due to decreased
choline acetyltransferase activity and the loss of forebrain cholinergic neurons (Wenk, 2003).

Amyloid Cascade Hypothesis
A majority of research on AD to date has focused on the role of amyloid β (Aβ) in
cognitive and neuronal dysfunction. Amyloid β peptide is formed by cleavage of amyloid
precursor protein (APP) first by β-secretases and then γ–secretases (Citron et al., 1996; Seubert
et al., 1993). Several isoforms of different lengths can be created, but the most common
isoforms are Aβ40 and Aβ42. While the soluble Aβ40 fragment is found in the cerebrospinal fluid
of both AD patients and normal controls (Seubert et al., 1992, Shoji et al., 1992), the Aβ42
fragment is more concentrated within neuritic plaques, and has therefore been more closely
associated with the disease (Roher et al 1993). (See Figure 1)
The discovery of Aβ within senile plaques led to the “amyloid cascade hypothesis,”
(ACH) which designates Aβ deposition as the initiating event in AD pathogenesis. According to
the amyloid cascade hypothesis, abnormal processing of APP results in overproduction of Aβ42
fragments which cannot be cleared effectively and accumulate in the brain (Hardy & Higgins,
1992). This deposition of Aβ is thought to be the initial event that causes the variety of changes
seen in the AD brain, including neurofibrillary tangles, neuronal death and cognitive decline
(Hardy & Higgins 1992; Reitz, 2012). The ACH is also supported by the link between earlyonset familial dementia and mutations in genes responsible for APP (Citron et al., 1992), as well
as genes for presenilin1 (PS1) and PS2 which are components of the γ-secretase complex
(Sherrington et al. 1995). (Figure 1)
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Figure 1. APP processing. Amyloid β is produced by the cleavage of APP, first by the βsecretase followed by the γ-secretase. Gamma-secretase can cleave at alternate sites to produce
either Aβ40 or Aβ42. Multiple known mutations that affect APP processing and Aβ production
can occur at various sites along APP and are linked with familial AD. For example, the Swedish
mutation is a well-known familial mutation that occurs at the beta-secretase cleavage site.
Several other mutations occur at the gamma secretase cleavage site. Mutations of gammasecretase itself, such as PS1Δe9, in which exon 9 of the presenilin1 component is deleted, result
in greater concentrations of harmful Aβ42 relative to Aβ40. Many of these mutations have been
used to engineer transgenic mouse models of AD. (Figure adapted from Hall and Roberson,
2012).

Despite the apparent involvement of Aβ in AD, several findings challenge the amyloid
hypothesis. First, clinico-pathologic studies have reported finding a high Aβ burden in the brains
of healthy individuals who do not qualify for a dementia diagnosis (Aizenstein et al., 2008; Lue,
Brachova, Civin, & Rogers, 1996; Lue et al., 1999). Although they likely represent a preclinical
stage of the disease, these high pathology, non-demented individuals show little evidence of
cortical synapse loss characteristic of neurodegenerative disorders (Lue et al., 1996). A second
challenge to the amyloid hypothesis comes from positron emission tomography (PET) studies
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using Pittsburgh Compound B (PIB), a marker for Aβ. On one hand, PIB uptake is significantly
increased in several cortical areas in patients diagnosed with AD relative to healthy controls and
some studies have identified an association between PIB uptake and clinical dementia severity
(Grimmer et al., 2009). However, studies looking at the relationship between Aβ load and
cognitive function (using either the mini mental status examination or a battery of
neuropsychological memory tests) have found either a weak correlation (Villemange et al., 2011)
or no correlation (Edison et al., 2008; Yokokura et al., 2011) suggesting that symptom
progression is due to downstream factors. Finally, treatments that target and remove Aβ
deposits, including active anti-Aβ vaccines (Holmes et al., 2008), passive anti-Aβ monoclonal
antibodies (Salloway et al., 2009, Salloway et al., 2014; Doody et al., 2014), and gamma
secretase inhibitors (Doody et al., 2013) have failed to stop progressive neurodegeneration and
cognitive decline in AD, even when successfully clearing amyloid plaques from the brain.

Alzheimer’s Disease and Inflammation
An alternative to the amyloid cascade hypothesis is that the neuron degeneration in AD is
due not to the Aβ plaques themselves, but to a dysregulated inflammatory response, perhaps
triggered by or aggravated by the amyloid deposits (McGeer, Rogers, & McGeer, 1994). There
is mounting evidence that implicates inflammation as a causal factor in disease progression.
This hypothesis is based on the finding of robust neuroinflammation in AD brains, characterized
by microglial and astrocytic activation and the upregulation of inflammatory markers such as
cytokines and chemokines (Shaftel, Griffin, & O’Banion, 2008). Inflammatory markers are colocalized to brain areas that are most affected by AD pathology such as the limbic cortex and
frontal lobes and tend to be expressed near amyloid plaques and neurofibrillary tangles
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(Akiyama et al., 2000). Inflammatory activation occurs very early in the disease progression,
often before other symptoms are observed. In transgenic AD mice, microglial and astrocytic
activation along with pro-inflammatory cytokine expression is observed before the formation of
amyloid plaques (Heneka et al., 2005).
Imaging studies have demonstrated a relationship between inflammation, as measured by
microglial activation, and AD symptom severity. A PET and MRI study of patients with early
AD showed an age-dependent increase in microglial activation relative to healthy controls,
correlating with areas of atrophy (Cagnin et al., 2001). Two PET studies using PK 11195, a
microglial marker, found a negative correlation between performance on neuropsychological
testing and microglial activation in the cortices of AD patients (Edison et al., 2008;Yokokura,
2011). These same studies failed to find a significant correlation between cognitive functioning
and Aβ load using PIB.

Components of the Inflammatory Profile in AD
Interleukin-1. IL-1 is an integral component of the inflammatory profile in AD. In
1989, Griffin and colleagues first reported elevated levels of IL-1 in the brain tissue of patients
with AD, including in IL-1 reactive microglia. Since then, a subset of AD research has focused
on the relationship between interleukin-1 mediated neuroinflammation and disease pathogenesis.
Elevations of IL-1 have also been demonstrated in rodent models of the disease (Benzing et al.,
1999).
IL-1 has been implicated as a key factor in promoting Aβ plaque pathology.
Overexpression of this cytokine is observed very early in the course of the disease, before
neuritic plaques are fully formed. The number of IL-1 reactive microglia correlates with the
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number of dystrophic neurites found in Aβ plaques (Griffin, Sheng, Roberts, & Mrak, 1995). IL1 directly contributes to amyloid deposition by promoting the synthesis of APP (Goldgaber et al.,
1989), and transforming diffuse β-amyloid aggregates into mature β-amyloid plaques (Griffin et
al., 1995). In APPswe mice, LPS-induced neuroinflammation increases the expression and
processing of APP and the accumulation of intracellular Aβ peptides (Sheng et al., 2003). In one
study, transgenic mice that expressed serum amyloid A, an acute phase protein, in the brain did
not show amyloid deposition unless injected with LPS, which increased levels of IL-1, IL-6 and
TNF-α (Guo, Yu, Grass, de Beer, & Kindy, 2002). The amyloid deposition in the brain was
significantly reduced when the LPS –treated animals were concurrently treated with a
nonsteroidal anti-inflammatory agent.
In AD, the chronic upregulation of IL-1β points to a dysregulated immune system in
which the innate pro-inflammatory response is unchecked. While IL-1 may promote Aβ
synthesis and deposition, Aβ itself can activate glial cells, inducing further production of IL-1β.
The result is more Aβ synthesis and deposition and increased neuronal injury, which causes even
more IL-1β to be released. This positive feedback amplifies the IL-1 expression and causes a
self-propagating “cytokine cycle” (Griffin et al., 1998).
IL-1 is also involved in promoting cholinergic dysfunction in AD. Acetylcholinesterase
(AChE), a postsynaptic enzyme that hydrolyzes acetylcholine at the synapse, is overactivated in
AD brains, especially by neurons associated with plaques. Implanting rat cortex with IL-1β
pellets induced an increase in AChE mRNA levels (Li et al., 2000). In vitro, microglial cultures
secreted IL-1 in response to fragments of APP, stimulating primary neuron cultures to upregulate
AChE activity (Li et al., 2000).
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Microglia. In AD, the inflammatory profile is characterized by increased numbers of
activated microglia, especially surrounding amyloid plaques. In normal brains, microglia are
distributed throughout the gray and white matter, but in the brains of humans with AD and also
in transgenic mouse models of AD, the microglia cluster around deposits of Aβ (El Khoury &
Luster, 2008). These plaque-associated microglia express significantly more IL-1 compared to
microglia in normal brains and non-plaque associated microglia in AD brains (Griffin et al.,
1989).
Microglia can exist in several levels of activation. In their quiescent state, they provide
surveillance for surrounding neurons (Lue, Kuo, Beach, & Walker, 2010; Town, Nikolic, & Tan,
2005). In the presence of injurious stimuli, microglia react quickly, releasing many substances
such as cytokines, chemokines, reactive oxygen species and adaptive immune-function
molecules. Microglia can also exist in a primed or sensitized state. Normally, microglia will
revert to the quiescent state after the body returns to homeostasis, but they can remain in a
chronic primed state when low levels of stimulation are present in the microenvironment (Lue et
al., 2010). In the primed state, they express several activation markers, such as major
histocompatibility complex II (MHC II), but low levels of pro-inflammatory cytokines.
However, in the presence of an immune stimulus, the resulting cytokine release is amplified and
prolonged (Wynne, Henry, & Godbout, 2009).
Microglial priming occurs in normal aging as part of a shift in the CNS
microenvironment from an anti-inflammatory to pro-inflammatory profile. In normally aging
brains, there is an upregulation of MHC II along with a decrease in mRNA expression of the
proteins IL-10 and CD200, which down-regulate glial activation (Frank et al., 2006). Primed
microglia in the aged brain are sensitized to produce exaggerated responses to additional stimuli.
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For example, peripheral infection produces a dramatic long-term increase in IL-1β in the
hippocampus of aged rats, but not in young rats, even though basal levels of IL-1β are not
consistently affected by age alone (Barrientos et al., 2009). In AD, age and amyloid deposition
could potentially combine to produce microglial activation and release of cytokines. In aged AD
transgenic animals relative to young animals and controls, LPS produces an exaggerated increase
in IL-1β levels in the hippocampus but not cerebellum where there are few amyloid plaques (Sly
et al., 2001). This finding suggests that both age and Aβ plaque accumulation prime microglia
leading to the heightened inflammatory state observed in AD.
It has recently been acknowledged that microglia (and macrophages in general) can take
on different activated phenotypes in response to different CNS insults. The M1 state, or classical
pro-inflammatory activation state, is induced by Th1 cytokines such as IFN-γ, TNF-α and IL-1β
(Varnum & Ikezu, 2012). Classically activated microglia release high levels of proinflammatory cytokines as well as reactive oxygen and nitrogen species, which kill pathogens
but also lead to cell damage (Colton, 2009). In contrast, M2 activation, also known as alternative
microglial activation, is induced by Th2 cytokines such as IL-4, IL-10 and IL-13 (Gordon, 2003).
M2 microglia express arginase 1, which inhibits NOS production; mannose receptor 1, which
activates anti-inflammatory signaling; and the genes FIZZ1 and YM1, which code for proteins
that help reconstruct the extracellular matrix (Colton et al., 2006). In the AD brain, a shift from
an M2 to M1 microglial activation is observed as the disease progresses. As APP/PS1 transgenic
AD mice age, more microglia in the hippocampus take on the classically activated phenotype
(Jimenez et al., 2008).
Astrocytes. Astrocytes also contribute to AD pathology. There is a positive correlation
between PIB binding of amyloid in PET scans of AD patients and amount of glial fibrillary
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protein-immunoreactive astrocytes upon autopsy (Kadir et al., 2011). In AD brains, astrocytes
are found surrounding both diffuse and neuritic Aβ plaques (Alarcon, Fuenzalida, Santibanez, &
von Bernhardi, 2005). Astrocytes in the entorhinal cortex accumulate neuronal material positive
for Aβ42 with the amount of material correlating to the level of local AD pathology (Nagele,
D’Andrea, Lee, Venkataraman, & Wang, 2003). Within the astrocytes, the amount of Aβ
correlates with neuron-specific proteins such as choline acetyltransferase, suggesting that the
astrocytic amyloid is acquired via phagocytosis of neuronal debris (Nagele et al., 2003). In vitro,
astrocytes are able to degrade and clear amyloid peptides in solution, but they are unable to clear
focal plaque-like deposits (Shaffer et al., 1995). The presence of activated astrocytes can even
inhibit microglial phagocytosis of amyloid plaque cores, perhaps allowing the plaques to
accumulate in AD (DeWitt, Perry, Cohen, Doller, & Silver, 1998; Shaffer et al., 1995).
Interleukin-1 can interact with astrocytes to promote AD pathology. IL-1α and IL-1β
increase synthesis of APP by up to 6-fold in primary human astrocytes by enhancing APP
mRNA translation (Rogers et al., 1999). IL-1 also causes astrocytes to overproduce s100β, a
neurotrophic factor responsible for promoting neurite growth (Mrak & Griffin, 2001). In fact,
increased s100β activity is seen in the temporal lobes of AD brains (Marshak, Pesce, Stanley, &
Griffin, 1992). There is a positive correlation between the number of plaque-associated
astrocytes expressing s100β and the amount of dystrophic neurite burden in the plaques,
suggesting that s100β is contributing to the pathogenesis of neuritic plaques (Mrak, Sheng, &
Griffin, 1996).
Leukocyte recruitment. Another component of the neuroinflammatory response is the
recruitment of peripheral leukocytes, such as monocytes, to the CNS. In the normal adult brain,
there are few leukocytes due to the presence of the blood brain barrier. However, under

14
pathological conditions such as in AD, monocytes and macrophages from the blood or bone
marrow enter the CNS and differentiate into microglia-like cells (Prinz, Priller, Sisodia, &
Ransohoff, 2011; Stalder et al., 2005). The recruitment of peripheral cells to the brain is
mediated by cytokines. In mice, experimental elevations of IL-1β cause several types of
leukocytes to migrate across the blood brain barrier (Shaftel et al., 2007a). These cells express
microglial markers but may have important functional and morphological distinctions (Simard,
Soulet, Gowing, Julien, & Rivest, 2006; Stalder et al., 2005).
Macrophages, like microglia, can be divided into classical (M1) and alternative (M2)
activation subsets. M1 macrophages are thought to be actively recruited from peripheral
circulation to the site of inflammation and to generate pro-inflammatory innate immune
responses (Gate, Rezai-Zadeh, Jodry, Rentsendorj, & Town, 2010). M2 macrophages can be
further broken down into M2a, M2b, and M2c subsets. M2a macrophages are phagocytic and
anti-inflammatory effector cells (Colton et al., 2006). M2b macrophages participate in the
clearance of reactive oxygen and nitrogen species (Gate et al., 2010). M2c macrophages are
involved in tissue healing (Varnum and Ikezu, 2012). Some have suggested that it is these
infiltrating peripheral macrophages, rather than resident microglia, that are driving the
differential classical vs. alternative activation types (Ransohoff & Brown, 2012).
In the past, microglia and non-resident monocytes were referred to interchangeably, but
recent research has begun to focus on the importance of distinguishing between the two. In a
study using their IL-1βXAT transgenic mouse model, which triggers overproduction of IL-1β
when activated, Shaftel et al. (2007a) demonstrated that experimental increases of IL-1β result in
an influx of leukocytes into the hippocampus, but no signs of neurodegeneration. In fact, studies
show that peripherally recruited macrophages are better able to phagocytose and clear amyloid
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plaques than their resident microglia counterparts (Simard et al., 2006). In transgenic AD mice,
genetically blocking TGFβ signaling induced an influx of M2 activated macrophages to the
brain, significantly increasing cerebral Aβ clearance (Town et al., 2008). These results suggest
that recruitment of peripheral macrophages expressing an M2 phenotype could be beneficial in
the treatment of AD pathology.
Blood Brain Barrier Breakdown. Related to the recruitment of peripheral cells to the
CNS is the finding of increased permeability of the blood brain barrier (BBB) in Alzheimer’s
disease and to a lesser extent, normal aging. The BBB is characterized by endothelial cells
connected by tight junctions and is a highly selective barrier separating the CNS from peripheral
circulation. Minogue et al. (2014) found an age-related increase in BBB permeability in the
hippocampus of APP-PS1 transgenic mice using both magnetic resonance imaging and
immunostaining for fibrinogen, which can accumulate in the brain across a damaged BBB. The
transgenic mice also showed greater BBB disruption compared to wild-type mice as well as
increased numbers of infiltrating immune cells, suggesting that vascular disruption and BBB
breakdown contributes to the migration of peripheral leukocytes into the brain. Another study
using rats showed that injecting them with Aβ1-42 resulted in increases in fibrinogen and
microgliosis, whereas concurrently inhibiting microglia with anti-Mac-1 resulted in a relatively
more intact BBB (Ryu and McLarnon, 2009). These findings suggest that glial cells interact
with the vasculature in AD to maintain neuroinflammation.
Autopsy studies of human AD brains have also demonstrated evidence of BBB
dysfunction. Fiala et al (2002) showed disruption in ZO-1, an endothelial tight junction protein,
in association with peripheral macrophages at the site of weakened vessels. Ryu and McLarnon
(2009) found greater fibrinogen leakage and immunoglobulin (IgG) reflective of a weakened
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BBB in AD brains compared to normal controls. A recent study using an advanced dynamic
contrast-enhanced MRI to look at regional BBB permeability found an age dependent breakdown
beginning in the hippocampus that is present in normal aging, but more pronounced in MCI
(Montagne et al., 2015). This finding suggests that increased BBB permeability is an early
contributor to cognitive dysfunction in AD.

Is Inflammation in AD Beneficial or Harmful?
There has been some debate over whether IL-1 driven inflammation is protective or
detrimental. As described above, IL-1β has been shown to contribute to cell death, but IL-1
expression in the brain can produce adaptive responses as well. In one study, exposing neuronal
cultures to high levels of IL-1β was neurotoxic, but low levels of IL-1β actually protected
against excitatory amino acid-induced cell death (Strijbos & Rothwell, 1995). Some have argued
that IL-1 plays a beneficial role in AD. Although cytokines may promote amyloid formation and
deposition, some studies show that that IL-1 reduces plaque pathology. In one study, Shaftel et
al. (2007b) crossed their IL-1βXAT mouse model, which contains a transgene that triggers
overproduction IL-1β in the hippocampus, with swAPP-PS1 transgenic mice, a mouse model of
Alzheimer’s-like pathology. They found a significant reduction in plaque pathology 4 weeks
after sustained IL-1β overexpression following transgene activation.
The proposed protective mechanism of IL-1 is through phagocytosis of amyloid plaques
by microglia and macrophages, which could be viewed as an M2 response, although all
microglia have phagocytic potential. The clustering of IL-1β -expressing, activated microglia
around amyloid plaques suggests an attempt at phagocytic removal of the Aβ (Griffin et al.,
1989). In vitro, microglia are effective in their phagocytic uptake of both amyloid aggregates
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(Paresce, Ghosh & Maxfield, 1996) and senile plaques (DeWitt et al., 1998). Microglia in the
AD brain contain fragments of Aβ, supporting their clearance and processing role (D’Andrea,
Cole & Ard, 2004). In early stages of the disease, microglial activation and recruitment of
monocytes from the periphery seem to delay the progression of AD-like pathology (El Khoury &
Luster, 2008; Simard et al., 2006). However, amyloid plaques continue to build up, despite the
continued microglial activation.
Microglia and monocyte-derived macrophages can exist in several activated phenotypes
that are determined by the local environment. The progression of most CNS diseases is from a
primarily inflammatory M1 phenotype to a more phagocytic M2 phenotype. However, in
chronic disease M1 activation is sustained. Microglia in the AD brain have reduced expression
of Aβ-binding receptors and Aβ degrading enzymes, but sill secrete pro-inflammatory cytokines
(Hickman, Allison, & El Khoury, 2008). In this state, phagocytosis is impaired and Aβ
clearance is reduced. In addition to their decreased Aβ-clearing effectiveness and IL-1β
production, the activated microglia also continue to produce reactive oxygen and nitrogen
species that are neurotoxic and cause neuronal degeneration (Weldon et al, 1998). The shift may
be caused by the presence of amyloid, which interacts with toll-like receptors and stimulates
microglial release of NO and TNFα (Lotz et al., 2005).
In other words, it may not be the strength of the immune activation, but the type of
response that is important. In human microglia cultures, activating an M1 phenotype inhibits Aβ
clearance, but adding the anti-inflammatory cytokines IL-4 or IL-10, which drive the M2
phenotype, promotes Aβ degradation (Yamamoto et al., 2008). Medeiros et al. (2013) found that
administering aspirin-triggered lipoxin A4 to 12-month-old Tg2576 mice, which harbor the
Swedish double mutation in APP, activated microglia to an M2 phenotype, resulting in improved
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phagocytic functioning and increased Aβ clearance, as well as improved performance on the
water maze.
The conformation of the Aβ can also influence the brain’s immune response. While
insoluble fibrillar Aβ42 can activate phagocytosis (Weldon et al., 1998), soluble oligomeric Aβ40
impairs the phagocytic functioning of microglia in vitro and inhibits ability to clear the Aβ fibrils
(Pan et al., 2011). The amount of MHCII positive microglia in the brains of patients and high
pathology controls is positively correlated with soluble Aβ in the neocortex, but not fibrillar
Aβ42 (Lue et al., 1996). Insoluble Aβ42 is found in neuritic plaques, but it does not correlate with
levels of synaptophysin, which indicates synapse and neuron loss (Lue et al., 1999). In contrast,
Aβ40 is correlated with synapse loss and can distinguish between demented individuals and high
pathology controls (Lue et al., 1999). These findings suggest that it could be the inflammatory
response to soluble Aβ, rather than the fully formed amyloid plaques themselves, that may be
responsible for driving the neurodegeneration in AD. This process could be driven by the release
of cytotoxic substances from M1 microglia and macrophages. In vitro, the induced suppression
of fibrillar Aβ phagocytosis can be blocked by incubation with anti-inflammatory cytokines,
COX inhibitors, and ibuprofen (Koenigsknecht-Talboo & Landreth, 2005), providing some
support for beneficial effects of anti-inflammatory treatments for AD.
NSAIDs and Anti-inflammatory Treatments
Prior research has explored the use of anti-inflammatory drugs as a therapeutic strategy
against AD. This strategy was first suggested when patients with rheumatoid arthritis using
chronic anti-inflammatory drugs were observed to have reduced rates of AD pathology (McGeer,
McGeer, Rogers, & Sibley, 1990). Since then, several epidemiological studies have linked long-
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term NSAID use to reduced risk of developing AD. A population based prospective study in
Rotterdam demonstrated that usage of NSAIDs was linked with a reduction in risk of AD and
that the relative risk declined as duration of NSAIDs increased (In t’Veld et al., 2001). In
transgenic animal models, chronic NSAID administration has been somewhat effective in
preventing or delaying the onset of amyloid deposition, dystrophic neurite formation and
inflammation (Lim et al., 2000).
Despite promising epidemiological data and findings with transgenic animals,
randomized clinical trials have not provided support for the therapeutic effectiveness of NSAIDs
against AD. Studies of patients with established AD have failed to demonstrate a protective
effect of various NSAIDs on either cognitive or functional decline (Scharf, Mander, Ugoni,
Vajda, & Christophidis, 1999; Aisen et al., 2003). Early results of ADAPT, a large scale
longitudinal study, revealed no significant reduction in risk of developing AD after treatment
with either celecoxib or naproxen (ADAPT Research Group, 2007), both of which inhibit COX.
The discrepancy in results suggests that the relationship between anti-inflammatory drugs
and AD is more complex than once thought. Factors such as age and phase of disease can all
play a role. In a study using older cohorts, NSAID treatment actually increased incidence of AD
(Breitner et al., 2009). This finding was interpreted with the hypothesis that NSAID use delays
AD onset and therefore will lead to a lower prevalence in younger cohorts but an increased
frequency in older cohorts. Leoutsakos and colleagues (2011) showed that the effects of NSAID
treatment in pre-clinical AD were different depending on whether the patients had a slow or
rapid rate of decline, suggesting that the role of inflammation may vary by phase of the
disease. It is also possible that a more incisive approach to anti-inflammation is needed. Some
components of the inflammatory response could be beneficial for inducing plaque clearance,
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while others could by cytotoxic, resulting in neuronal loss. This potential subtlety suggests the
need to more deeply understand the roles of individual inflammatory mediators like IL-1 in the
pathogenic process.
Human Gene Profiling Reveals Gene Linkage for Interleukin-1 and AD
Genetic studies have associated risk for developing AD with certain polymorphisms in
genes for several inflammatory agents, with the strongest link involving IL-1α and IL-1β
(McGeer & McGeer, 2001). Several studies have shown a correlation between the IL-1α -889
regulatory region and risk of AD. Grimaldi et al. (2000) found that carrying the TT genotype of
this polymorphism, which exists in C and T forms, doubles the likelihood of developing AD.
This TT genotype was also strongly associated with an earlier age of onset, with carriers of the
genotype showing a mean age of onset 9 years earlier than those with the CC genotype. Nicoll et
al. (2000) examined a large population of people from centers in the UK and US and found that
12.9% of confirmed AD patients had a TT genotype for IL-1α, compared to only 6.6% of healthy
controls. A recent meta-analysis based on 32 case-control studies found a significant link
between the homozygous -889T allele and susceptibility to AD, with an odds ratio of 1.2 (Qin et
al., 2012).
Two polymorphisms in the gene for IL-1β have also been associated with risk of AD.
Homozygosity for the T allele of the +3953 polymorphism, which increases IL-1β production by
4 times compared to a C/C allele, was found to occur in 7.3% in AD patients compared to 4.8%
in healthy controls (Nicoll et al., 2000). Individuals who carried homozygous T alleles for both
IL1A -889 and IL1β +3953 were 10.8 times more likely to develop AD (Nicoll et al., 2000). A
meta-analysis of 8 studies found a significant correlation between the IL-1β +3953
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polymorphism and AD, with carriers of the TT genotype about 1.6 times more likely to have the
disease than subjects with CT or CC genotypes (Di Bona et al., 2008).
Grimaldi et al. found a higher risk of late-onset AD in people with a T/T genotype for the
-511 polymorphism of the gene for IL-1β (Grimaldi et al., 2000). However, a meta-analysis
based on 16 studies did not reveal a significantly greater prevalence of the T/T genotype of IL-1β
-511 in AD patients than controls, except when analyzing only Caucasian studies with the
highest statistical power (Di Bona et al., 2008).
Interleukin-1 and Normal Function/Memory
There has been substantial evidence linking pro-inflammatory cytokines to impairments
in learning and memory processes. Hippocampal long-term potentiation (LTP), which is critical
for memory consolidation, is impaired by brain elevations of IL-1β in CA1 (Bellinger,
Madamba, & Siggins, 1993), CA3 (Katsuki et al., 1990), and the dentate gyrus (Cunningham,
Murray, O’Neill, Lynch, & O’Connor, 1996). Administration of IL-1β directly to CA1 region of
the rat hippocampus in vitro altered synaptic potentials and inhibited LTP (Bellinger et al.,
1993). Recombinant human IL-1β, when added to the mossy fiber CA3 pathway of mouse
hippocampus in vitro, inhibited LTP even in very low concentrations (2.9pM) (Katsuki et al.,
1990). Pre-treatment of rat hippocampal slices with IL-1β inhibited induction of LTP in the
dentate gyrus, whereas co-application of IL-1ra eliminated the effect (Cunningham et al., 1996).
The disruption of LTP by IL-1β has been demonstrated in vivo as well. In rats,
intraventricular injection of IL-1β significantly increased IL-1β levels in the dentate gyrus and
significantly decreased ability to sustain LTP (Murray & Lynch, 1998). The peritoneal
administration of LPS in rats increased IL-1β expression in the hippocampus and inhibited LTP
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in perforant path granule cell synapses (Vereker, O’Donnell, & Lynch, 2000b). The decreased
LTP was also accompanied by increases in reactive oxygen species, lowered glutamate release,
and cell degeneration in the hippocampus and entorhinal cortex. Although these changes are
correlative, they can be blocked by concurrent inhibition of caspase-1, further implicating IL-1β
as the mediator of these degenerative effects (Vereker, Campbell, Roche, McEntee, & Lynch
2000a)
Studies using behavioral tests on rodents have demonstrated impaired memory processes
in conjunction with increased IL-1β expression in the rodent hippocampus. In mice,
administration of exogenous IL-1, LPS or live bacteria impairs spatial learning and retention on
the Morris Water Maze (Gibertini, Newton, Friedman, & Klein, 1995; Arai, Matsuki, Ikegaya, &
Nishiyama, 2001). Injection of LPS to the rat hippocampus also impairs learning and memory
on a passive avoidance test (Tanaka et al., 2006). When LPS is injected with an interleukin-1β
inhibitor, memory impairments are attenuated (Tanaka et al., 2011). Blocking the effects of IL-1
through administration of the IL-1 receptor antagonist resulted in facilitation of both short and
long term memory in a fear-motivated learning task in rats (Depino et al., 2004). In one study,
peripheral administration of LPS disrupted learning after one day of training but not after 4 days
of training when learning had plateaued, suggesting that the impaired performance is a result of
impaired memory consolidation, rather than sickness behavior (Sparkman, Kohman, Garcia, &
Boehm, 2005).
The memory impairments induced by IL-1β are affected by age, with old mice more
affected than younger mice. One study showed performance impairments on hippocampaldependent fear memory tests in aged, but not young, rats after E. coli-induced increases in brain
IL-1β levels (Barrientos et al., 2006). In contrast, their performance on a hippocampal-
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independent memory task was unaffected. Similarly, intraperitoneal injection of LPS after
training on an active avoidance-learning task disrupted memory consolidation for old mice
compared to young mice (Tarr et al., 2011). The impaired performance persisted after sickness
behavior had dissipated, as measured by escape/avoidance latencies and motor behavior.
Despite the abundance of research showing the detrimental effects of IL-1β
overexpression, there is also evidence that IL-1 signaling is necessary for normal hippocampal
memory functioning. IL-1β gene expression is increased in the hippocampus during LTP, and
blocking IL-1 receptors using IL-1ra impairs the maintenance of the LTP (Schneider et al.,
1998). Low doses of IL-1β can actually improve performance on avoidance memory tests
(Brennan, Beck, & Servatius, 2003). When IL-1 expression is eliminated, as in IL-1R1 knockout
mice, the result is impaired LTP and hippocampal memory formation (Avital et al., 2003). As a
result of these findings, Goshen and colleagues (2007) proposed that the effect of IL-1 on
memory follows an inverted U-shaped curve. In other words, a certain amount of IL-1 signaling
is important for memory, but deviations from that amount in either direction cause impairments.
They provided support for this model, showing that intracerebroventricular injections of either
IL-1ra or high doses of IL-1β impaired performance on a contextual fear conditioning test, but
small doses of IL-1β actually improved performance (Goshen et al., 2007).

IL-1 and Other Behavioral Symptoms of AD
Depression. There is also evidence that IL-1 may impact some of the non-cognitive
symptoms of AD. IL-1 induces sickness behavior, which bears many similarities to depression,
including withdrawal from the physical and social environment, decreased motor activity,
malaise, anhedonia and decreased food intake (Dantzer, O’Connor, Freund, Johnson, & Kelley,
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2008). The similarities between these behavioral profiles suggest that cytokine-induced
depression represents a maladaptive form of sickness behavior. However, despite the overlap
between the two conditions, cytokines can cause depressive symptoms beyond sickness-related
behaviors. In patients receiving cytokine immunotherapy, sickness behavior symptoms are
universal at first, but only about one third of those patients develop major depressive episodes
(Capuron, Ravaud, & Dantzer, 2000). Treatment with antidepressants can prevent the depressed
mood and anhedonia associated with the cytokine therapy, but has no effect on fatigue and
anorexia (Capuron et al., 2002). In an animal study, mice treated with LPS showed depressivelike behaviors on a forced swim test and a tail suspension test at 24 hours, after sickness-induced
motor suppression had returned to normal (Frenois et al., 2007). The same LPS-treated mice
showed decreased preference for sucrose solutions despite normal food and water consumption.
These results demonstrate a dissociation between depression and sickness-related behaviors
despite the overlap between the two.
Several actions of IL-1β have been used to explain the associated depressive
symptomatology. IL-1β activates serotonin transporters, increasing serotonin reuptake in
synaptosomes from mouse midbrain and striatum (Zhu et al., 2006). Also in mice, LPS induces
delayed cellular activity in the limbic system, corresponding to the development of depressivelike behaviors (Frenois et al., 2007). IL-1 activation of the HPA axis may also contribute to the
resulting depression. Over activity of the HPA axis is observed in patients with depression,
characterized by increased levels of corticotropin-releasing hormone in the brain (Pariante,
2003).
Anxiety and the Stress Response. Alzheimer’s patients also commonly exhibit
symptoms of anxiety and agitation (Porter et al., 2003; Mega et al., 1996), which may be
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associated with inflammation and IL-1 elevations. As mentioned previously, IL-1 is an integral
component of the body’s stress response mechanism, mediated by the hypothalamic pituitary
adrenal (HPA) axis. In both acute and chronic stressful conditions, the HPA becomes activated
resulting in a cascade of events. First, the hypothalamus releases corticotropin-releasing factor
(CRF), which triggers the pituitary gland to release adrenocorticotropic hormone (ACTH), which
then travels via the blood stream to the adrenal cortices, stimulating the release of glucocorticoid
hormones. These glucocorticoids then travel back to the hypothalamus and pituitary to suppress
ACTH production, thus completing the negative feedback loop that regulates the acute stress
response (Laugero 2001). Prolonged or severe stress and HPA activation can be harmful.
Several studies have showed that stress along with expression of glucocorticoids (cortisol) is
associated with atrophy in the hippocampus of both humans and animals, along with deficits in
memory, inhibition of neurogenesis, and decreased levels of certain growth factors (see Bremner,
2006 for review).
Research with rodent models has helped demonstrated the link between cytokines and
anxiety. Mice injected with IL-1 show HPA activation along with increases in noradrenaline and
serotonin, which are both implicated in anxiety and depression (Dunn, 2000). Behavioral tests of
anxiety, such as the elevated-plus maze and the light-dark preference test, tend to focus on
approach and exploratory drives, particularly in novel settings. Animals exhibiting more anxiety
will avoid the exposed arms of the elevated plus maze and avoid the light portion of the lightdark apparatus. These tests have been validated by the alteration of responses following
introduction of anxiolytic medications (Belzung & Griebel, 2001). Swiergiel and Dunn (2007)
demonstrated that administering either Il-1beta or LPS induced dose-dependent decreases both in
open arm entries and time spent in the open arms on the elevated plus test, reflecting increased
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anxiety. In contrast, mice with decreased IL-1 activity, due to transgenic overexpression of the
IL-1 receptor antagonist, show reduced anxiety both the elevated plus (Oprica et al., 2005) and
the light-dark tests behavioral tests (Spulber & Schultzberg, 2010).
In non-clinical and clinical human populations, there are correlations between
proinflammatory cytokines and stress/anxiety. Maes et al., (1998) found that medical students
expressed elevated levels of proinflammatory cytokines the day before an exam with higher
levels of self-reported anxiety corresponding to the higher levels of cytokines. Patients with
combat-related post-traumatic stress disorder (PTSD) were shown to have higher IL-β serum
levels correlating with the duration of anxiety symptoms (Spivak et al., 1997). Taken together
with the animal research, these studies suggest a complex relationship between cytokines, the
stress response, and anxiety.

IL-1 and Other Neurodegenerative Diseases
Aside from AD, IL-1 has been associated with other neurodegenerative disease. In
Parkinson’s disease, elevated levels of Il-1 elevations are reported in nigrostriatal dopaminergic
regions (Mogi et al. 1994). Further, Tanaka et al. (2013) found that injecting LPS into the
substantia nigra of mice resulted in microglial activation, IL-1β and TNFα production, as well as
motor deficits, cell death, and aggregation of α-synuclein. These changes were not seen in IL1R1 knockout mice. IL-1 is also implicated in multiple sclerosis (MS), a chronic inflammatory,
autoimmune, demyelinating disease of the CNS, which is associated with cognitive impairment
in about half of patients (Nistico et al., 2014). MS patients have increased IL-1β in peripheral
blood mononuclear cells (Heidary et al., 2014) and in CSF, with CSF levels of IL-1β at clinical
onset correlating with cortical lesion load and cortical thickness (Seppi et al., 2014). In rats with
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experimental autoimmune encephalomyelitis (EAE), an experimental model of MS, IL-1β is
expressed by macrophages and microglia in both white and gray matter at sites of early lesion
formation (Prins et al., 2013). In amyotrophic lateral sclerosis, increased IL-1β levels are found
in the CSF and spinal cord of ALS patients as well as SOD1 mutant mice, an animal model of
the disease (van der Meer and Simon, 2010). Blocking IL-1 by inhibiting caspase-1 slows the
disease progression (Friedlander et al., 1997). Finally, Il-1 has also been linked to other brain
diseases including Creutzfeldt-Jakob disease (Van Everbroeck et al., 2002) and HIV-1
encephalitis (Zhao et al., 2001).

IL-1 as a Key Player in Alzheimer's-like Cognitive Deficits
Taken together, the studies presented in this review make a strong case for IL-1 as a key
player in Alzheimer’s-like cognitive deficits. However, the inflammatory component of AD is
complicated and a clear view of IL-1’s exact role in pathogenesis is still developing. The mixed
effectiveness of anti-inflammatory treatment highlights the complexity of the role of
inflammation in AD. Potential therapeutic strategies may need to target individual components
of the inflammatory response, such as IL-1. If chronic overexpression of IL-1 is responsible for
driving the AD pathology and its associated cognitive impairments, chronic inhibition of this
cytokine could be beneficial in treating the disease. Many studies described above have used IL1ra to block the effects of IL-1 in the short term. Another pharmaceutical strategy is the use of
an immunoadhesin or trap reagent. One such reagent is the IL-1 Trap or rilonacept (Regeneron
Pharmaceuticals). The IL-1 Trap consists of a forced IL-1 receptor 1 homodimer fused to a
mouse Fc fragment. This trap binds IL-1 at a high affinity, preventing it from binding to its
endogenous receptor, and therefore serves as an antagonist of IL-1 signaling (Economides et al.,
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2003). Using transgenic mice that overexpress mutated pathogenic APP, one could start
treatment at the point when symptoms and pathology usually become evident to determine
whether IL-1 inhibition would slow and/or reverse disease progression. In order to have the
most impact, treatment should begin early in the disease course. Although starting treatment
much earlier may be more effective at preventing the pathological signs of the disease from
developing, is not as relevant to clinical populations, as people usually do not start treatment for
Alzheimer’s Disease before any symptoms develop. Therefore, the best approach would be to
initiate treatment at time points when symptoms have appeared. After a period of chronic
treatment with this drug, memory could be assessed to look for cognitive improvement using
behavioral tests such as the Morris Water Maze. It would also be important to assess the effect
of chronic IL-1 inhibition on the deposition of amyloid plaques, as well as on microglial
activation and investment. This research would help to further elucidate any causal relationship
between IL-1, neuroinflammation, and AD pathology.

The following specific aims are proposed to address the role of IL-1 signaling in the behavioral
and anatomical pathology of Alzheimer’s-like disease:
Specific Aim 1: To examine the effect of chronic systemic inhibition of IL-1 signaling on
learning and memory in AD model transgenic mice and wild type controls.

Specific Aim 2: To determine whether chronic systemic inhibition of IL-1 signaling affects
amyloid plaque pathology in the brains of AD model transgenic mice.
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Specific Aim 3: To determine whether chronic systemic inhibition of IL-1 signaling affects
microglial density and size in the hippocampus of AD model transgenic mice, both in general
and surrounding amyloid plaques.

Specific Aim 4: To determine whether quantitative measures of amyloid plaque pathology and
microglial measures are predictive of performance on measures of learning and behavior in AD
transgenic model mice, and whether chronic inhibition of IL-1 signaling alters this relationship.
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Chapter 2
GENERAL METHODS
Subjects
Subjects were 40 male mice run in two cohorts of 20 mice each. The transgenic mice
used in the first cohort were on a C57Bl/6 background (The Jackson Laboratories, Stock number
= 005866). Due to problems with availability of this strain, the mice used in the second cohort
were from a slightly different background lineage (Jackson Laboratories, Stock number =
004462). C57Bl/6 mice were used as the recommended wild type controls (Stock number =
000664). Of each cohort, ten of the mice were wild type (WT) animals and ten were tandem
transgenic (Tg) for both the Swedish pedigree mutation in the amyloid precursor protein
(Mo/HuAPP695swe) and the high Alzheimer’s risk polymorphism in presenilin-1 (PS1-dE9).
The mice were housed either singly or in small groups of three or fewer animals per cage.
All animals were initially housed in small groups and only separated in the case of fighting. Due
to concerns that isolation can have significant effects on animal behavior, a log linear analysis
was conducted to make sure that the number of singly housed animals was evenly distributed
across groups. The results of this analysis revealed no difference between genotypes and
treatment groups (G2(4)=3.2, p=.52). Animals were housed in a temperature-stabilized facility
on a 12:12 light:dark cycle (lights on 07:00), with food and water available ad libitum. All
procedures were conducted with approval from and in strict compliance with the animal welfare
policies of the Institutional Animal Care and Use Committee of Queens College of the City
University of New York.
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Experimental Design and Timeline
Animals were received from Jackson Laboratories at about 12 weeks of age. They were
introduced to their home cages and allowed to acclimate and age until behavioral testing was
initiated. Animals were given the open field test at about 5 months of age to assess for baseline
locomotor activity. At about 8 months of age, when previous studies have reported the
emergence of behavioral and anatomical abnormalities, injections began and continued for 5
months. During the fifth month of treatment, behavioral testing was conducted to evaluate
learning and memory as well as general locomotor activity and anxiety. After the completion of
behavioral testing, animals were perfused and their brains were collected and prepared for further
analysis.

Proteins and Injections
In order to inhibit interleukin signaling, animals were administered either mouse IL-1
Trap, which consisted of a forced homodimer of the extracellular binding domain of IL-1
receptor 1 fused to mouse Fc fragments, or the protein control mFc (a generous gift from
Regeneron Pharmaceuticals, Tarrytown, NY, USA) starting at about 8 months of age. Both the
mIL-1 Trap and mFc were kept frozen (at -80°C) until use and were then thawed and diluted in
sterile phosphate-buffered solution (PBS) (Sigma-Aldrich, St. Louis, MO, USA). Within each
cohort, five TG animals and five WT animals received mouse IL-1 Trap (mIL-1 Trap) at a dose
of 10 mg/kg. The rest of the mice received mouse Fc (mFc) at the same dose and volume to
control for protein load (Table 1). Injections were administered subcutaneously twice per week.
Mice were weighed weekly in order to establish dosage and evaluate animal health. The
injections continued for 5 months.
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Because the IL-1 trap was administered peripherally in this experiment, it was not known
how much, if any, of the compound would reach the brain. The mIL-1 trap is a large protein and
therefore is not likely to cross over the blood brain barrier. The purpose of this study was to
assess the clinical efficacy of the drug in AD-like pathology and therefore, the exact mechanism
by which peripheral IL-1 inhibition has its effect was not the main focus of our experiments.
However, if peripheral mIL-1 Trap administration has no measurable effects on either behavior
or pathology, it would raise the question of whether the drug has no effect, or whether it simply
failed to reach its target. In that case, further work would need to be done to differentiate
between these possibilities.

Tissue Collection and Processing
After 5 months of treatment, the animals were sacrificed and brains were prepared for
histological analysis. Twenty-four hours after their last mFc or mIL-1 Trap injection, all animals
were overdosed with a pentobarbital-based euthanasia solution. Cold heparinized isotonic (0.9%)
saline was perfused transcardially to exsanguinate the animal, followed by perfusion with 4%
paraformaldehyde first in acetate, and then borate buffer (100ml each). Upon completion of the
perfusion, brains were removed and placed in 30% buffered sucrose for 3-7 days. The fixed
brains were then sectioned coronally at 50µm using a sliding microtome (American Optical
Company, Buffalo, New York). Sections were placed into a 24-well plate and stored in an
ethylene glycol based cryoprotectant solution (Watson et al., 1986) at -20°C until they were
stained.
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Table 1. Experimental Design

Wild Type
SwAPP/PS1 Transgenic

mFc
10
10

mIL-1 Trap
10
10
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Chapter 3
BEHAVIORAL TESTING

The most prominent neuropsychological deficit in AD patients is impaired verbal and
spatial memory. Animal models of the disease also demonstrate impairments in hippocampallymediated memory tasks such as spatial mazes (Hall and Roberson, 2012). Since memory is the
first and most prominent functional impairment in AD, the most important question for any
treatment is whether it can slow or prevent this functional memory decline. There is growing
evidence that implicates IL-1 as a contributor to AD pathology (Shaftel et al., 2008). In addition,
elevated IL-1 levels have been linked to impairments in hippocampal long-term potentiation
(Bellinger et al., 1993; Katsuki et al., 1990; Cunningham et al., 1996) as well as impaired
performance on the Morris Water Maze (Gibertini, Newton, Friedman, & Klein, 1995; Arai,
Matsuki, Ikegaya, & Nishiyama, 2001). In contrast, blocking IL-1 protects against memory
impairments on other hippocampal-dependent tests (Tanaka et al., 2011). Therefore, we
hypothesized that long term inhibition of IL-1 using the mIL-1 Trap in transgenic mice would
preserve learning and memory, as assessed by the Morris Water Maze.
In addition to learning and memory, we assessed general locomotor activity. Alzheimer’s
transgenic mice have shown alterations in general locomotor and exploratory behaviors
(Lalonde, Fukuchi, & Strazielle, 2012). Because of Il-1’s role in sickness-related behaviors,
including decreased motor activity, withdrawal from the physical and social environment, and
general malaise (Dantzer, O’Connor, Freund, Johnson, & Kelley, 2008), it is possible that long
term IL-1 inhibition could alter exploratory and locomotor activity as measured on the Open
Field test. It was especially important to assess for Open Field activity as a control for memory
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performance, because differences in activity level can influence water maze performance.
Finally, the elevated plus maze and light dark test were conducted as measures of anxiety-like
behaviors.

Methods.
Morris Water Maze. The Morris Water Maze Test was conducted in order to evaluate
spatial learning and memory. A pool measuring 105 cm in diameter and 35cm in depth was
filled with water made opaque with non-toxic white paint. The pool was then divided
conceptually into four quadrants, one of which contained an escape platform hidden 2.5 cm
beneath the surface. Animals were placed in a different, pseudo-randomly selected quadrant at
the start of each trial, and the latency to escape the maze onto the hidden platform was measured.
There were two trial blocks per day for five days, each consisting of three one-minute trials.
Between trials, animals were held with a towel for approximately 30 seconds before being placed
back in the water. After each block, they were placed in a holding cage lined with towels until
dry and then returned to their home cages. The testing was conducted at the same time each day
with a 3-hour interval between the first and second daily blocks. Any animal not locating the
platform within one minute was assigned a latency of 60 seconds and guided to the platform by
hand before being removed from the water. Normal animals are expected to demonstrate a
decrease in latency to escape across trials in the water maze, indicating acquisition of the
location of the platform over time.
One hour after the final block of water maze acquisition testing, animals were returned to
the maze for a 30 second probe trial with the platform removed to test their retention of the
platform’s location. Retention was assessed by measuring the amount of time animals spent in
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the quadrant that formerly housed the platform, termed the “goal quadrant.” The number of
times the animals swam over the spot where the platform was located was also counted.
Animals with normal retention are expected to spend more time in the “goal quadrant” than in
other quadrants and to make more “platform crosses”, thus demonstrating retention of the spatial
location of the escape platform.
For each trial block, the animals’ median latency to escape the maze across the three
trials was recorded and these median latencies were used for statistical analysis. In addition,
animals’ swim speeds were estimated by dividing latency to escape by the number of maze
quadrants crossed per trial to calculate mean quadrant crossing time as a surrogate for swim
speed. The median quadrant crossing time for each trial block was used for statistical analysis.

Open Field. The Open Field test was conducted in order to assess basic locomotor
activity. Animals were placed into a white, box-like apparatus measuring 48 wide x 48 long x 24
high cm with the inside floor divided into nine grids, each measuring 16 x 16 cm. Animals were
placed in the center grid and allowed to freely explore the apparatus for a six-minute trial. An
animal was considered to have crossed from one grid to another when at least three paws crossed
over the grid line. The number of total grid crossings was recorded as a measure of general
locomotor and exploratory behavior. Rearing behaviors, defined as any time an animal stood up
on its hind legs, were recorded as another measure of exploratory activity.

Elevated Plus Maze. The elevated plus maze test was conducted to assess anxiety-like
behaviors. The apparatus was composed of a platform measuring 15 x 15 cm elevated 114 cm
on a central pole. Four arms were joined to the platform, each measuring 61 x 15 cm, arranged
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in a plus-shaped configuration and equal in height relative to the platform. Two of the arms were
white, open platforms oriented directly across from each other. Perpendicular to the open arms
were two black arms enclosed by walls measuring 30 cm high. Animals were placed on the
platform and allowed to freely explore the maze for five minutes. The number of seconds the
animals spent on the platform and in the open and closed arms was recorded. Increased time
spent in the closed arms is traditionally considered indicative of heightened anxiety, as rodents
tend to avoid open, brightly lit areas that are unfamiliar or might expose them to danger from
airborne predators. The total number of arm entries was also recorded as a measure of locomotor
activity as well as the proportion of entries made to the closed arm as a second measure of
anxiety-like behavior. This test was conducted with all animals two weeks before the first
injection to establish a baseline before treatment. The test was conducted again 2 weeks prior to
sacrifice, after almost 5 months of treatment.

Light-Dark Exploration. The light-dark exploration test was conducted as an additional
measure of anxiety-like behavior. Animals were placed in a rectangular apparatus measuring 45
long x 20 wide x 20 cm high, half of which was white and open at the top (the “light” side), and
half of which was black and covered (the “dark” side). Animals were placed in the center of the
light side and allowed to freely explore the apparatus for five minutes. The amount of time
animals spent in the light and dark sides, respectively, was recorded. As in the elevated plus
maze, increased time spent in the dark, enclosed portion of the apparatus is considered indicative
of increased anxiety.
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Statistical Analysis. For water maze acquisition, the median latency to escape onto the
goal platform was recorded for each animal for each trial block. A three-way mixed Factorial
analysis of variance (ANOVA) was conducted using treatment and genotype as the between
groups independent variables and trial block as a repeated measure variable. For retention, the
proportion of time spent in the goal quadrant was recorded for each animal along with the
number of platform crosses. Two-way ANOVAs (genotype x treatment) were conducted with
each of these as dependent variables.
To evaluate locomotor activity and exploratory behavior, the number of grid crossings in
the open field test was counted for each animal. The number of times an animal engaged in
rearing behavior was also recorded. A two-way ANOVA (genotype x treatment) was conducted
using the number of total grid crossings as well as rears.
The elevated plus and light dark tests were both conducted as measures of anxiety. For
the elevated plus, the proportion of time spent in the closed arm was recorded for each animal.
In addition, number of total arm entries was recorded as a measure of overall exploratory activity
and the proportion of those entries made to the closed arm was calculated as another measure of
anxiety. Two-way ANOVAs (genotype x treatment) were conducted for these dependent
variables. For the light dark test, the proportion of time spent in the dark side was recorded and
two-way ANOVA (genotype x treatment) was conducted.
For each measure, the analyses were run first using cohort as a factor in order to assess
for cohort effects. This was especially important because the background strains used between
the first and second cohort were slightly different, raising concerns that the treatment could have
affected the cohorts differently. If there were no interactions between cohort and treatment, the
data were collapsed across cohorts.
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Results
General Health. Mice were weighed and evaluated weekly to assess their general health.
Out of the original 40 animals, 37 survived to sacrifice. In the first cohort, one transgenic animal
in the mFc-treated group died before the behavioral testing stage. From the second cohort, one
transgenic animal in the mIL-1 Trap group died before the behavioral testing stage and one wild
type animal in the mIL-1 Trap group died after completing some behavioral testing. At the final
weighing before perfusion, the transgenic mice weighed about 27% less than the wild type mice
(F(1,33)=55.46, p<.001) (Figure 2). Although the transgenic mice weighed less, they were
actually closer to the normal body weight for adult male mice (Mazzaccara et al., 2008), and
appeared grossly healthy. The mIL-1 Trap had no negative impact on body weights (F(1,33)
=0.00, p=.994) and the mice appeared grossly healthy throughout the study.
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Figure 2. Average weight of each group throughout the treatment.
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Water Maze. A three-way mixed Factorial ANOVA (genotype x treatment x trial block)
showed that the wild type animals performed significantly better overall than the swAPP/PS-1
double transgenic animals in water maze acquisition (F(1,33)=29.71, p<.001), as expected based
on previously published data. The mIL-1 Trap had no significant overall effect on water maze
performance (F(1,33)=2.76, p=0.11), but there was a significant interaction between the two
factors (F(1,33)=4.61, p=.039; Figure 3), with the Trap selectively improving performance in the
transgenic animals. An analysis of cohort effects revealed a significant cohort by genotype
interaction, such that the transgenic animals of the second cohort performed worse overall than
those in the first cohort. However, there was no cohort by treatment effect and no cohort by
genotype by treatment effect, indicating that the Trap affected the mice similarly across both
cohorts.
We also assessed whether differences in swim speed could be influencing our findings by
evaluating mean quadrant crossing time for the animals. Slower swim speeds have been reported
in transgenic AD mice (Ying et al., 2010), which can interfere with an animal’s latency to swim
to the platform. A three-way mixed Factorial ANOVA (genotype x treatment x trial block)
revealed no significant differences in quadrant crossing time across genotype (F(1,33)=.61,
p=.442) or treatment (F(1,33)=1.13, p=.296), and no genotype by treatment interaction
(F(1,33)=.47, p=.50). In addition, we did not see any significant general locomotor differences
in the open field test (see Open Field section), suggesting that motor differences did not account
for the acquisition results observed.
On the retention portion of the water maze, wild type animals spent significantly more
time in the goal quadrant (F(1,33)=18.83, p<.001) and made significantly more platform crosses
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(F(1,33)=8.86, p=0.005) than transgenic animals, confirming the previously-reported memory
impairment in the Alzheimer’s model transgenics. There was no significant effect of mIL-1 Trap
treatment on proportion of time spent in the goal quadrant (F(1,33)=.313, p=.58) and there was
no interaction between the factors (F(1,33)=.04, p=.84) (Figure 4). There was also no significant
effect of treatment on number of platform crosses (F(1,33)=2.29, p=.14) and no interaction
between treatment and genotype (F(1,33)=.1.63, p=.21) (Figure 5). An additional two-way
ANOVA was performed to look at escape times in the final block of water maze acquisition
(block 10) alone to see how the animals differed shortly before the retention phase. At this point,
the transgenic animals showed a statistical trend toward longer latencies to escape to the platform
compared to wild type animals (F(1,33)=3.018, p=.092). However, there was no significant
overall effect of treatment (F(1,33)=2.689, p=.111) and no interaction between genotype and
treatment (F(1,33)=.122, p=.729) at this point. This additional analysis suggests that by the end
of water maze acquisition, the animals had all eventually learned the maze to a similar level.
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Figure 3. Water Maze Acquisition. Wild type animals performed significantly better overall
than transgenic animals in water maze acquisition (F(1,33)=29.71, p<.001). There was a
significant interaction between genotype and treatment (F(1,33)=4.61, p=.039), such that the
mIL-1 Trap improved acquisition performance for transgenic animals.
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Figure 4. Water Maze Retention (time in goal quadrant). Wild type mice spent significantly
more time in the goal quadrant than transgenic animals. However, there was no significant effect
of treatment and there was no interaction between the factors. ***p<.001
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Figure 5. Water Maze Retention (number of platform crosses). Wild type mice made
significantly more platform crosses than transgenic animals. There was no significant effect of
treatment on number of platform crosses and no interaction between factors.

To further explore differences in the learning process between these groups, an additional
set of water maze analyses were conducted. First, different scores were obtained for all blocks
occurring on the same day (eg. block 2 minus block 1), yielding 5 within-day difference scores.
Then, difference scores were obtained using the first block of one day and the last block of the
day before (eg. block 3 minus block 2), yielding 4 difference scores. This was done to look at
differences in memory consolidation by assessing learning that occurred overnight. Difference
scores for both within-day and overnight were compared for both genotypes and treatment
groups across all days of the Water Maze test. Data were analyzed using a mixed factorial
ANOVA with difference scores across test days as the within-subjects factor and genotype and
treatment as between-groups factors.
Regarding within-day analyses, no differences were found overall in difference scores
across the 5 days. That is, the extent to which the animals’ scores changed from the first to
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second block of the day did not differ throughout the course of the 5-day test (F(4,132)=.500,
p=.736). There were also no between-groups differences between genotype (F(1,33)=.429,
p=517) or treatment group (F(1,33)=1.429, p=.241), and no interaction (F(1,33)=1.425, p=.241).
When the overnight difference scores were analyzed, a significant effect of test day was
found (F(3,99)=3.518, p=.018) Overall, the difference scores were negative for day 1-2
(indicating learning) and became more positive as the test went on, suggesting that there was
learning occurring overnight early in the experiment and that the overnight boost lessened as the
test progressed. There was also a significant effect of treatment, such that animals treated with
mIL-1 Trap had significantly lower overnight difference scores (indicating better learning) than
animals treated with mFc (F(1,33)=5.353, p=.027). This suggests that treatment with the trap
improved memory consolidation overnight. Interestingly, there was no significant effect of
genotype on this measure (F(1,33)=.210, p=.650) and no interactions with genotype and
treatment (F(1,33)=.138, p=.713).

Open Field. In order to examine baseline differences by genotype in locomotor activity
and exploratory behavior, the number of overall grid crossings was compared between wild type
and transgenic animals at 4-5 months old. A t-test revealed that transgenic mice made
significantly fewer grid crosses than wild type animals (t(38) = 3.18, p=.003) (Figure 6a)
Transgenic mice also made significantly fewer rears than wild type animals (t(38) = 3.512,
p=.001) (Figure 6b).

This suggests that swAPP-PS1 mice show a reduction in general

locomotor activity and exploratory behavior at 4-5 months of age.
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Figure 6. Open field results for 4-5 old animals. 4-5 month old transgenic animals made
significantly fewer grid crosses (a) and significantly fewer rears (b) on the Open Field test
relative to wild type controls. **p<.01, **p≤.001.
The open field test was conducted again after 4 months of treatment with the mIL-1 Trap
at which point the mice were approximately 12 months old. A two-way ANOVA (genotype x
treatment) was conducted to examine differences in total number of grid crossings. Overall,
there was no difference in total number of grid crossings between wild type and transgenic
animals (F(1,33)=.699, p=.409), and no difference between animals treated with mFc and those
treated with mIL-1 Trap (F(1,33)=.18, p=.673). There was no interaction between genotype and
treatment (F(1,33) =.03, p=.873) (Figure 7a). Whereas younger transgenic mice made fewer
rears than wild type controls, as older mice, the transgenics showed a trend towards making more
rears than wild types, although this did not reach statistical significance (F(1,34)=3.107, p=.087).
There was no overall difference between the two treatment groups (F(1,34)=.011, p=.918) and no
genotype by treatment interaction (F(1,34)=.000, p=.984) (Figure 7b). These results suggest that
although there were differences seen in locomotor activity as 4-5 month old animals, transgenic
mice did not differ significantly in overall level of locomotor activity compared to wild type
mice at 8-9 months of age, and that level of activity was not affected by treatment with mIL-1
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Trap. Since the second run of open field was conducted within two weeks prior to water maze
testing, these results suggest that differences in water maze performance are not likely to be
explained by differences in general activity and/or exploratory behavior. Our finding of no
significant differences among the groups in mean quadrant crossing time in the water maze
further suggests that locomotion was not a confounding variable in our cognitive tests.
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Figure 7: Open field results for 8-9 month old animals. A) No differences were found in
total number of grid crossings based on genotype or treatment and there was no interaction
between genotype and treatment. B) transgenic mice showed a statistical trend toward making
more rears than wild types, but there was no overall difference between the two treatment groups
and no genotype by treatment interaction.
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Elevated Plus Maze. In order to assess anxiety-like behaviors, the elevated plus test was
conducted in one cohort of animals, both right before beginning treatment with mIL-1 Trap and
approximately one week before perfusion. The proportion of time spent in the closed arms was
compared between the two genotypes. A t-test revealed that young transgenic mice spent
significantly more time in the closed arms compared to the wild-type animals (t(18)=4.612,
p<.001) (Figure 8a). This result suggests a heightened level of anxiety in 7-month old transgenic
mice compared to their wild type counterparts. The transgenic animals made fewer total arm
entries than the wild type animals, suggesting reduced exploratory activity on this test
(t(18)=3.596, p=.002) (Figure 8b). The transgenic animals also showed a statistical trend
towards making a higher proportion of their arm entries into the closed arms (t(18)=2.018,
p=.064) (Figure 8c).
When the elevated plus test was run 5 months later, there were no longer any differences
in the anxiety measures between groups. A two-way ANOVA (genotype x treatment) showed no
significant difference in time spent in the closed arms between wild type and transgenic animals
(F(1,14)=.000, p=.994), no significant effect of treatment (F(1,14=1.501, p=.238) and no
significant interaction between genotype and treatment (F(1,14)=.200, p=.66) (Figure 9a). When
analyzing the data in terms of proportion of closed arm entries, there was also no difference
between genotypes (F(1,14)=.000, p=.987), no effect of treatment (F(1,14)=.177, p=.680) and no
genotype by treatment interaction (F(1,14)=1.157, p=.300) (Figure 9c). Unlike the Open Field
test, however, old animals did show a difference in overall activity on the elevated plus.
Transgenic mice at 12 months of age still made significantly fewer overall arm entries than wild
type animals (F(1,14)=6.162, p=.026). There were no differences between treatment groups
(F(1,14)=1.040, p=.325) and no interaction (F(1,14)=1.307, p=.272) (Figure 9b).
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Figure 8. Elevated plus results for 7-month old animals. a) At 7 months of age, transgenic
animals spent a significantly greater proportion of time in the closed arms than the wild type
animals. b) They made significantly fewer entries overall, but c) showed a statistical trend
(p=.064) towards making a higher proportion of those entries to the closed arms.
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Figure 9. Elevated Plus results for 12-month old animals. a) At 12 months of age, there were
no longer any differences between genotypes in time spent in the closed arms of the apparatus.
There was also no effect of treatment with mIL-1 Trap and no interaction between treatment and
genotype. B) Transgenic mice made significantly fewer overall arm entries than wild type
animals, but there were no differences between treatment groups and no interaction. C) There
were no differences in proportion of closed arm entries between genotypes and treatment groups,
and no interaction.
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Light-Dark Test. A second test of anxiety was conducted following the elevated plus
maze test in the aged animals only. The proportion of time spent in the dark half of the apparatus
was compared using a two-way ANOVA (genotype x treatment). Similar to the elevated plus
maze, there were no differences found between wild type and transgenic animals (F(1,16) = .057,
p=.815) or between animals treated with mIL-1 Trap vs. mFc (F(1,16)=2.573, p=.128). There
was no significant genotype x treatment interaction (F(1,16)=.282, p=.603) (Figure 10).
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Figure 10. Light Dark proportion of time spent in dark side. At 12 months, there were no
significant differences in time spent in the dark half of the apparatus between the transgenic and
wild type animals, no affect of treatment, and no genotype by treatment interaction.

Interim Discussion
Our findings indicate that the mIL-1 Trap selectively improved water maze performance
in the Alzheimer’s model transgenic animals. This pattern of behavioral results suggests that IL1 inhibition can slow the cognitive decline resulting from overexpression of mutant Presenilin-1
and the Swedish APP mutation without impacting performance in normal mice. The effects of
IL-1 inhibition shown here are in agreement with shorter term studies that link sustained
overexpression of hippocampal IL-1β in mice with impaired spatial memory, glial activation, and
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increased pro-inflammatory cytokine expression (Hein et al., 2010; Moore et al., 2009). A study
using a transgenic rat model of Alzheimer’s disease demonstrated improved spatial memory,
decreased hippocampal neuronal loss, and reductions of hippocampal IL-1β and TNFa levels in
rats treated with Tetrandine (He et al., 2011). In the present study, Il-1 inhibition improved
acquisition while having no effect on retention, suggesting that the treated mice may have used
compensatory strategies to assist with their performance of the task.
The extra water maze analyses of difference scores from blocks within the same day and
overnight suggest that the Trap is boosting memory by affecting memory consolidation.
Specifically, animals treated with mIL-1 Trap showed a greater boost in memory from the last
trial of one day to the first trial of the next when compared to the mFc treated animals. However,
this was only observed as a main effect of treatment that did not interact with genotype. This
suggests that the effects of IL-1 inhibition on overnight memory consolidation were beneficial
for both transgenic and wild type animals and therefore, it may not explain the selective
improvement of trap treated transgenic animals on the overall test. But, if the IL-1 traps memory
effects are most evident when looking at memory from one day to the next, it could be that the
period between the last acquisition trial and the retention probe were not long enough to see
differences, which could explain the lack of effect seen between treatment groups on this probe
trial.
One important question that is often ignored in animal studies is how the behavioral
testing can be linked to cognitive performance in humans. Specifically, can we draw parallels
from the water maze to human cognitive testing? Clinically, a diagnosis of AD is usually based
more on verbal tests, which obviously cannot be conducted with rodents. However, spatial
disorientation and getting lost is a common symptom of early AD (McShane et al., 1998;
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Guariglia and Nitrini, 2009). On objective testing, visuospatial memory deficits are observed in
AD patients. Okonkwo et al (2014) reported that baseline performance on the Brief Visuospatial
Memory Test-Revised (BVMT-R), which involves learning and delayed memory of visual
figures and their locations, was the best predictor of cognitive decline in a cohort of cognitively
normal middle-aged adults (age 40-65). In the Baltimore Longitudinal Study of Aging, making
more errors on the Benton Visual Retention Test was associated with an increased risk of an AD
diagnosis up to 15 years later (Kawas et al., 2003). In addition, a study of non-demented oldest
old adults (ages 82-95) demonstrated that immediate and delayed memory of a complex figure
(Rey Osterreith) declined significantly more over a 7-9 year period in those with a positive
amyloid PET than those with a negative PET scan (Snitz et al., 2013).
Although the aforementioned neuropsychological tests are grouped in the category
visuospatial learning and memory, the tasks may differ from navigating and remembering a
maze. There have been some attempts to more directly translate these rodent tests to humans and
tap into these spatial navigation deficits, using real world and virtual reality paradigms. Astur et
al (2002) actually developed a virtual Morris Water Maze task to show that humans with
hippocampal resections had spatial navigation impairments relative to those with resections in
other brain areas, although this was not conducted in AD patients. Cushman et al. (2008) found
significant differences in navigational ability and spatial memory using real world and virtual
reality environments such that those with early AD performed worse than early MCI who
performed worse than controls.
Even with these more targeted spatial tests, important differences remain. First, the time
course of human testing vs. animal testing is different. Even when several learning trials are
used, as in the human virtual water maze, the time of the test is compressed relative to animal
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testing, which can span several days. Also it may be impossible to completely remove the verbal
component from human cognitive testing. In Cushman et al’s (2008) study, delayed verbal
memory along with virtual reality performance, was a significant predictor of real world
navigational performance. Performance on spatial tests could partially be influenced by verbal
deficits influencing the ability to name landmarks or construct a narrative of a visual scene or
navigational path. Despite these limitations, it is important to consider the application of any
testing with rodent models to human patients.
In addition to learning and memory, past studies have used tests such as the open field to
examine changes in locomotor and exploratory activity in transgenic animals. Several studies
have shown hyperactivity in Alzheimer’s model transgenic strains, including in the Tg2576 line
(Lim et al., 2001) and the swAPP/PS1 strain used in the present study (Cheng et al., 2013). We
did not replicate these findings and in fact found a significant pattern of hypoactivity in the
younger transgenic mice. However, a thorough look at the literature reveals a more complex
relationship between AD mutations and locomotor activity, which may depend on the task
parameters, sex of the animals, and the transgenic strain used (Lalonde et al., 2012). Though
many studies show open field hyperactivity, others show no locomotor differences. Lalonde,
Kim, and Fukuchi (2004) found no difference in open field activity in 7-month-old male and
female swAPP/PS1 (delta e9) mice relative to wild type controls. Other studies looking at
models with slightly different swAPP and PS1 mutations even found hypoactivity, including Liu
et al. (2002) who found reduced open field locomotor activity and rearing in 7 month old male
swAPP PS1(A246E) mice. This variability is also reflected in humans with AD, as some may
exhibit signs of agitation while others experience apathy and decreased activity (Di Iulio et al.,
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2010; Chung & Cummings, 2000). The reasons for this variability are still not completely
understood.
Age also appears to be a factor with many transgenic models showing changes in activity
level throughout the life span. In the present study, by the time the mice were older (12 months),
any differences in open field activity across groups had disappeared. Locomotor activity no
longer differed between genotypes. Age-related changes from hypo- to hyperactivity have been
reported in APP751SL mice from 2 months to 19-20 months (Blanchard et al., 2009) and from 6
months to 24 months in APP23 mice (Dumont et al., 2004). One study using 10-14 month old
male swAPP/PS1(dE9) mice, the exact strain used in this experiment, found no difference in
open field locomotor activity or rearing (Hartmann et al., 2010). Since motor activity of normal
mice decreases with age (Lalonde et al., 2012), if the predominant phenotype of this transgenic
strain is hypoactivity, it would make sense that the differences are more apparent when the mice
are young.
Despite previous research showing some support for anti-inflammatory treatment
affecting locomotor activity (Lim et al., 2001), we did not find any effect of treatment with mIL1 Trap on open field activity. Since the primary purpose for including this measure was as a
control for learning and memory tests, the main conclusion of these results is that differences in
water maze performance between treatment groups cannot be attributed to changes in locomotor
activity or exploratory behavior.
In addition to differences in overall locomotor activity between young transgenic and
wild type animals, we also found a significant difference on the elevated plus test, which is used
as a measure of anxiety. Young (7 month) transgenic animals spent significantly more time in
the closed arms of the apparatus than the wild type controls. Increased time in the closed arms is
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thought to indicate heightened anxiety since the animals avoid brightly lit areas that could expose
them to danger from predators. As with the open field test, the behavior of TG mice in the
elevated plus test depends on several factors, including the exact model, sex and age of the mice
and parameters of the task. In contrast with our results, Lalonde and colleagues found increases
in open arm exploration, suggesting disinhibition, in 7-month-old (2004) and 12-month-old
(2005) swAPP/PS1 mice, the same model used in the present study. However, not all studies
have revealed the same pattern. Studies using transgenic models with slightly different APP and
PS1 mutations than the mice used here showed no difference between transgenic and wild type
mice at 6 months (Filali, Lalonde, & Rivest, 2011) and heightened anxiety at 14 months
(Puolivali et al., 2002).
The results of the elevated plus also shed light on our young open field findings. The
open field test is most often used as a measure of locomotor activity but it involves placing the
animals in a novel environment, which can be intrinsically anxiety provoking. Viewed through
the lens of increased anxiety, the reduced overall activity and number of rears in young
transgenic animals could be viewed as anxious “freezing” behavior
When the animals were older (12 months old), the elevated plus test no longer revealed
any differences between the two genotypes. Wild type and transgenic animals spent a similar
amount of time in the closed arms and there was no effect of treatment with the mIL-1 Trap. The
light dark test was performed as second test of anxiety in the older animals and also revealed no
differences between any groups. It is possible that the heightened levels of anxiety seen in the
earlier testing signify a prodromal stage of AD that wanes as the disease progress. It also may be
that the animals become acclimated to repeated testing throughout the experiment and no longer
experience an anxiety response to these stimuli. In order to fully differentiate between these
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possibilities, more detailed behavioral testing would need to be conducted across the life span of
these animals. For purposes of this study, the lack of differences in anxiety measures between
the older groups further supports our conclusion that improvements on the water maze test are
due to improved learning and memory rather than anxiety provoked behavioral arrest.
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Chapter 4
AMYLOID PLAQUE ANALYSIS

One of the most prominent pathological features of AD is the presence of amyloid
plaques throughout the cerebral cortex. Since the discovery of amyloid β protein in senile
plaques, the question of amyloid’s role in AD has driven a large portion of AD research. For
decades, studies have focused on the amyloid cascade hypothesis (ACH), stating that deposition
of Aβ is the trigger responsible for the pathological and functional changes seen in AD (Hardy
and Higgins, 1992; Reitz 2012). Although support for the ACH has waned in recent years,
amyloid is still a focus of AD research both in humans and animal models. In fact, many
transgenic AD mouse models utilize genes responsible for processing of APP that are linked to
familial AD (Citron et al., 1992; Sherrington et al., 1995). Thus, in many transgenic AD mouse
models, including the swAPP-PS1 model used here, amyloid plaques are the most obvious
pathology.
Because of the importance of Aβ plaques in the brains of these mice, it was important to
assess the effect of long term IL-1 inhibition on amyloid plaque deposition. There is evidence
that IL-1 may contribute to Aβ plaque pathology by promoting APP synthesis (Goldgaber et al.,
1989) and by encouraging the formation of mature plaques from β amyloid aggregates (Griffin et
al, 1995). Inducing IL-1 expression with LPS has been shown to increase APP and Aβ
accumulation (Sheng et al., 2003, Guo et al., 2002). As shown in the previous chapter, chronic,
systemic inhibition of IL-1 using mIL-1 Trap in these transgenic mice resulted in a significant
improvement in water maze performance compared to mice not given IL-1 Trap. Our next goal
was to try to determine whether this inhibition of IL-1 was also associated with a reduction of
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amyloid plaque pathology. If the mIL-1 Trap had decreased the number or size of amyloid
plaques in the hippocampus, this could provide an explanation for the improvement in memory
functioning.

Methods
Histology. Sections were stained in a 1:12 series in Congo Red (Sigma-Aldrich C6767)
to detect the presence of amyloid plaques (protocol in Wilcock, Gordon & Morgan, 2006). The
sections were first mounted on slides and allowed to air-dry overnight. After rehydrating in
distilled water, slides were incubated first in an 80% ethanol solution saturated with NaCl and
then in Congo Red solution (0.2% Congo Red in 80% ethanol saturated with NaCl). They were
then rinsed in 95% and 100% ethanol, cover-slipped with xylene-based mounting medium and
allowed to dry overnight. All excess adhesive was removed from the dry slides using a glass
cleaning solution.
Image Analysis. Amyloid plaque burden was analyzed by contrast analysis using the
Image J image analysis software program (NIH). For each animal, a minimum of 2 bilateral
sections of hippocampus were photographed at 10x. However, the method used for capturing
images were slightly different from cohort 1 to cohort 2 because of improvements in imaging
technology available that occurred between cohorts. For cohort 1, images were captured in 10x
using the Picture Frame program. Pictures were taken in one session to minimize differences in
illumination between images. For cohort 2, slides were placed in the slide rack compartments
(hotels) of an automated imager (Leica, Model SL801). The imager was set to scan all slides up
to the maximum magnification of 40x. These scanned images were then uploaded to an internetbased network (Slidepath). Digital images were captured for each sample at a magnification of

59
10x and stored. For both cohorts, once the images were captured, the red color of the stain was
isolated using the eyedropper tool in Adobe Photoshop in each picture, and the background was
faded to achieve contrast. Identical processing parameters were used for all sections in each
experiment, regardless of treatment group. The entire image was then desaturated in order to
convert it to black and white, imported to Image J, and converted to a binary image (Figure 11).
The contrast analysis was performed on these binary images using the Analyze Particles
command in Image J, which measured the proportion of area stained, number of separate
plaques, and average plaque size for each image. For each animal, the values obtained for all
images were averaged and the means for area stained, number of plaques, and average plaque
size were used for further statistical analysis.
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Figure 11. Preparing images for contrast analysis. The original image of hippocampus is
shown photographed at 10x (A). First, the color of the plaques was selected and then copied and
pasted as a second layer. The background layer was then converted to grayscale (B) and set to
maximum lightness (C) in order to isolate the plaques. The entire image was then desaturated
(D) and imported to ImageJ where it was converted into a binary image (E).

Statistical Analysis. To assess differences in plaque pathology between wild type and
transgenic animals that received the mIL-1 Trap vs. the mFc, two-way ANOVAs (genotype x
treatment) were conducted for each of the following measures: amyloid plaque proportion of
area covered, plaque count, and average plaque size.
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Results
Plaque Burden Analysis. The plaque burden contrast analysis revealed that swAPP/PS1 transgenic mice had significantly more plaques (F(1,26)=13.49, p<.001), more total area
covered by plaques (F(1,26)=210.06, p<.001), and a higher average plaque size (F(1,26)=58.12,
p<.001) than the wild type animals. (Figure 13). Indeed, no Congo red-positive plaques were
observed in any wild type animal (Figure 12). The contrast analysis did seem to pick up a small
amount of background stain, which resulted in a small proportion of area covered by plaques to
be reported as an artifact for wild type animals. Because the wild type animals did not show
amyloid plaque pathology, they were excluded from subsequent plaque analyses. Three 2x2
ANOVAs were run with transgenic animals alone using treatment and cohort as factors. There
was no significant difference between animals given mIL-1 trap versus mFc on the proportion of
area covered by plaques (F(1, 14)=.102, p=754), number of plaques (F(1,14)=.002, p=.969), or
average size per plaque (F(1,14)=.44, p=.516). There was a significant cohort effect for plaque
area covered, plaque count, and average size per plaque such that cohort 2 had a greater area of
the hippocampus covered by plaques, more plaques, and a larger average plaque size. However,
there was no cohort by treatment interaction indicating that the treatment with mIL-1 Trap had
no effect on either cohort. The differences between the cohorts on these measures may be due to
a lighter overall stain with the second group and the different methods used to capture the images
between the cohorts, both of which may have resulted in fewer plaques being detected in the
contrast analysis for cohort 2.

62

mFc

mIL-1 Trap
B

C

D

Transgenic

Wild Type

A

Figure 12. Staining of representative hippocampal sections with Congo Red (photographed
at 10x). Scale bar (blue) = 200µm
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Figure 13. Results of contrast analysis for hippocampal plaque burden. Plaque burden was
significantly increased for transgenic animals, with higher proportion of hippocampus covered
by plaques (a), higher plaque counts (b), and bigger average plaque size (c). There were no
differences between those treated with mFc vs. mIL-1 Trap on any of the plaque measures.
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Interim Discussion
Based on prior literature, we initially hypothesized that chronic IL-1 inhibition would
result in reduced amyloid plaque pathology. Past research has linked high levels of IL-1 to
enhanced Aβ production and plaque deposition (Griffin et al., 1998, Shaftel et al., 2008). In fact,
in one study, injection of synthetic IL-1β resulted in increased β-APP expression in rat brains
(Sheng et al., 1996). However, our contrast analysis of amyloid plaques in the mouse
hippocampus revealed no effect of the mIL-1 Trap. Long-term, systemic inhibition of IL-1β did
not reduce overall hippocampal plaque burden and had no effect on number of plaques or their
average size.
These plaque analysis results taken together with water maze data provide an interesting
look at the nature of AD-like pathology in the swAPP/PS1 transgenic mice. The inhibition of
IL-1β improved spatial learning in these mice without reducing the amount of amyloid plaques in
the brain, suggesting that factors other than β-amyloid deposition are contributing to their
cognitive deficits. One explanation is that the mIL-1 Trap may be improving memory by
inhibiting the immune response to the plaques without reducing the plaques themselves.
Therefore, the next goal of the study was to determine whether inhibition of IL-1 had any effect
on components of the immune response that could explain the differences in performance on
behavioral testing.
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Chapter 5
MICROGLIA ANALYSIS

In addition to the main pathological hallmarks of AD, including amyloid plaques and
hyperphosphorylated tau, the AD brain is characterized by a robust neuroinflammatory response
that includes elevation of pro-inflammatory cytokines and activation of immune cells. In
particular, microglia that express elevated levels of IL-1 are associated with amyloid plaques in
brains of patients with AD (Griffin et al., 1989). Although the clustering of microglia around
plaques suggests an attempt at phagocytosis, amyloid continues to build up as the disease
progresses. Chronic elevations of IL-1 in the AD brain may cause microglia to remain in a
sustained, classically activated state with potentially suboptimal clearance of Aβ and continued
release of cytotoxic substances (Weldon et al., 1998).
In this study so far, transgenic mice treated with chronic systemic mIL-1 Trap
demonstrated improved performance on the Morris Water Maze relative to mFc treated
transgenic mice. However, the absence of any effect of the Trap on amyloid plaque pathology
prompted us to look for effects on components of the immune that may explain the behavioral
changes. Microglia are a prime target to explore because of the prominence of activated
microglia, particularly those expressing IL-1, in the AD brain. Since IL-1β is known to trigger
microglia to a classical activation state, long-term inhibition of Il-1β with the mIL-1 trap may
reduce microglial activation or at least shift activation to a more phagocytic, anti-inflammatory
M2 state. Because classical microglial activation is linked to impairments in learning and
memory in PET studies (Edison et al., 2008; Yokokura et al., 2011), it is plausible that treatment
with the mIL-1 Trap induced changes in microglial activation, which could potentially explain its
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behavioral effects. In addition, M2 microglia are known to secrete elevated levels of growth
factors, and these have the potential to induce beneficial neurotrophic effects.
One way to quantify the immune response using microglia would be to study them
anatomically by looking at differences in the number of microglia as well as in microglial
morphology. We expected that inhibition of IL-1 might result in fewer microglia present in the
hippocampus, especially surrounding amyloid plaques. In addition, we had hypothesized that the
animals treated with mIL-1 Trap would show alterations in the size of their microglia somas. In
order to examine differential response to amyloid plaques, we measured size for microglia that
were adjacent to plaques as well as those that were farther away. Differences between mFctreated and Trap-treated animals on these measures would indicate that IL-1 inhibition altered
the microglial profile in response to the plaques even if the plaques themselves were not reduced.

Methods
Iba-1 immunostaining. In order to assess characteristics of microglia in these mice, an
Iba-1 immunostain was performed. Microglia express Iba-1 even at low levels of activation,
which makes it an appropriate antibody for assessing microglial presence and morphology.
Sections were immunostained in a 1:12 series using Iba-1 antibody (rabbit polyclonal, Millipore,
Inc.) at a dilution of 1:500, with overnight incubation at 4° C. Sections were incubated with
biotinylated goat anti-rabbit secondary antibody (Vector Laboratories) at a dilution of 1:1500 at
room temperature for one hour. Avidin-biotin-peroxidase complex (ABC Elite Kit, Vector
Laboratories) was applied for one hour at room temperature. The stain was then visualized using
nickel-enhanced diaminobenzidine (DAB). To more precisely assess the relationship between
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microglia and amyloid plaques, the Iba-1 immunostain was repeated with additional sections and
counterstained with Congo Red in the second cohort.
Microglia analyses. The overall number of microglia in the hippocampus was estimated
in both wild type and transgenic mice by first pseudorandomly sampling two fields of view in the
CA1, CA3, and dentate gyrus each. An acetate sheet with a 45µm by 45µm grid of dots was
placed over the screen at 10x and all microglial profiles within the plane of focus that fell on a
dot were counted. The average number of microglial profiles per field was averaged for all of
the fields and analyzed statistically.
The next step of the microglia analysis was to measure overall changes in microglia soma
size to evaluate potential differences in microglial phenotype for those glia contacting amyloid
plaques. As microglia become activated, their shape changes. The cell body enlarges and
processes retract as the cell shifts from a resting state with surveillance properties to an activated
cell ready for phagocytosis. Microglia activated to a classical or M1 phenotype express proinflammatory cytokines such as IL-1β as well as nitric oxide synthase (NOS) and other reactive
nitrogen and oxygen species that can lead to neurotoxicity and damage to the extracellular
matrix. On the other hand, microglia expressing an alternative or M2 phenotype are antiinflammatory, release markers arginase-1, IL-10, and TGF-β, and are involved in phagocytosis
(M2a phenotype), deactivation of glial inflammation, and wound healing (M2c phenotype;
Varnum and Ikezu, 2012). Slides containing tissue double-stained with Iba-1 and Congo Red
were scanned at high resolution. In each transgenic animal, images of plaques were captured
within CA1, CA3, and the dentate gyrus of the hippocampus. In order to randomly select
plaques to be imaged and measured, an acetate sheet with a 45µm x 45µm grid was laid over the
screen with the tissue zoomed at 10x over a region of the hippocampus. Any plaque falling on
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any dot in the grid was selected for measurement. These images were then taken at 40x and
imported to Image J by an experimenter blind to the animal genotypes and treatments. This
method yielded about 4-7 plaque images per area per animal.
For each image, the diameter and area of the plaque were measured. Only plaques with a
diameter of 10µm or bigger were used. For each plaque, the soma of three proximities of
microglia were traced and analyzed for soma area and sphericity. All visible microglia that were
physically touching the plaque were considered plaque-adjacent. Microglia that were close to
plaques, but not in physical contact with them, were considered plaque-proximal. To identify
plaque-proximal microglia, a circle was drawn around the plaque in Image J 30µm from the
plaque edge on all sides. All microglia that were within this circle, but not touching the plaque
were considered plaque-proximal. In addition, microglia not associated with plaques
(completely outside the circle but still within the field of view) were measured within each
region for comparison to peri-plaque microglia in order to see whether the mIL-1 Trap
differentially affected morphology of peri-plaque vs. plaque-distant microglia. Microglia were
excluded from the plaque-distant measurements if they were within 30µm of another plaque or
within 30µm of the edge of the image.
Microglia soma size was also measured in the hippocampus of the wild type animals in
order to establish a baseline for comparison for the plaque-distant microglia. Although we
would ideally obtain measurements of wild type mice treated with both mFc and mIL-1 Trap,
technical problems with the scanner prevented us from obtaining some images from the double
stained Iba-1/Congo Red slides. Therefore, microglia were measured in the wild type-mFc
group to serve as a reference point.
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For each plaque used in the microglia volume analysis, the number of adjacent microglia
was also recorded and then combined for each animal in order to generate an average number of
microglia per plaque. The same was done for the proximal microglia. These values were then
used for statistical analysis to assess whether the number of microglia that were either near or
touching plaques differed between transgenic animals treated with mIL-1 Trap vs. mFc. These
measures could obviously not be conducted for wild type animals, because no wild type animal
exhibited plaques.
Hippocampal Volume. Finally, in order to ensure that any differences in microglial
density were not due to shrinkage of the tissue, measurements were taken for hippocampal
volume. This measure also allowed us to evaluate any hippocampal atrophy that could have
occurred as a consequence of either chronic IL-1 Trap treatment or of expression of the
Alzheimer’s transgenes. Sections were stained with Cresyl Violet for detection of Nissl bodies.
Hippocampi were measured using the Cavalieri Probe in StereoInvestigator (MBF Bioscience).
Anterior hippocampus sections in a 1:6 series were selected and traced for each animal
throughout the dorsal hippocampus. Six bilateral sections of hippocampus were measured for
each animal. For each section, a grid pattern (of grid size 50 x 50µm2) was randomly laid over
the tissue and all grid points falling within the traced area were selected. The probe estimated
the volume of this section of hippocampus for each animal.
Statistical analysis. To compare microglial counts, the average number of microglial
profiles per field in each hippocampal area (CA1, CA3, and dentate gyrus) were averaged to
yield one number for each animal. A two-way ANOVA was then conducted using genotype and
treatment as independent variables. For the microglial volume analysis, after the microglia
somata were traced for each image, the values were combined for each animal for each category
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(plaque-adjacent, proximal, and distant). The microglia volume values were then analyzed to
detect any outliers, defined as greater than two standard deviations from the mean for each
animal in each category. Any outliers were removed from further analysis. To assess
differences in microglia soma area, a 2x3 factorial ANOVA was conducted using treatment and
distance from plaque as independent variables. This analysis was conducted for whole
hippocampus.
The number of microglia that were adjacent to and proximal to each plaque used in the
volume measurement was averaged for each animal. A t-test was conducted for each of these
values to compare the mFc group and the mIL-1 group.
Finally, the hippocampal volume estimates obtained from the Cavalieri probe were
analyzed using a two-way ANOVA with genotype and treatment as independent variables.

Results
Microglia density and distribution. There was a slight statistical trend toward
transgenic animals having more microglia in the hippocampus overall (F=3.263, p=.094).
However, there was no effect of treatment (F=2.666, p=.126) and no genotype by treatment
interaction (F=.171, p=.686) (Figure 15a). We ran additional analyses to determine whether
there were differences in microglial density between groups for three hippocampal sub-regions.
A similar pattern was found in CA3 with transgenic animals showing a trend towards a higher
number of microglia than wild type animals (F=3.690, p=.077) but no effect of mIL-1 Trap
treatment (F=1.794, p=.203) and no interaction (F=.000, p=.986). In CA1 and the DG, there was
no difference between genotypes (CA1: F=2.021, p=.179; DG: F=1.758, p=.208), no difference
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between treatment groups (CA1: F=1.290, p=.277; DG: F=2.225, p=.160) and no interactions
(CA1: .368, p=.554; DG: F=.123, p=.731).
Although the overall number of hippocampal microglia present did not differ between
groups, observation of the hippocampus of wild type vs. transgenic animals revealed a difference
in distribution of the cells. Whereas wild type animals showed a uniform distribution of
microglia, transgenic animals showed clusters of microglia throughout the hippocampus (Figure
14 a-b). A second Iba-1 immunostain counterstained with Congo Red confirmed that these
microglia were clustered around amyloid plaques (Figure 14c). To assess whether the treatment
with IL-1 Trap affected this recruitment of microglia to the amyloid plaques, the average number
of microglia adjacent to (soma touching) plaques in the hippocampus was compared for
transgenic animals across treatment groups. There was no difference between transgenic animals
treated with mFc and mIL-1 Trap in average number of plaque-adjacent microglia (soma
touching the plaque, t(6)=-1.045, p=.336) or plaque-proximal (microglia within 30µm of a
plaque but not touching it, t(6)=.940, p=.383) (Figure 15 b-c).
We then examined whether number of microglia adjacent to and proximal to plaques
differed between treatment groups in the CA1, CA3, and DG regions of the hippocampus. There
was a statistical trend toward fewer plaque-proximal microglia in CA3 for the mIL-1 Traptreated animals compared to mFc-treated animals (t(6)=2.249, p=.066). There were no other
differences in number of plaque-adjacent or plaque-proximal microglia between the treatment
groups in any of these regions.
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Figure 14. Representative images of staining of hippocampus with Iba-1 and Congo Red.
a-b) Images of hippocampus stained for Iba-1 photographed at 10x. a) Wild type animal with
evenly distributed microglia. b) Transgenic animal showing clusters of microglia. c)
Hippocampus of a transgenic animal immunostained with Iba-1 for microglia and counterstained
with Congo Red for amyloid shows microglia clustering around amyloid plaques. Scale bar
(yellow) = 200µm
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Figure 15. Number of microglia per field and per plaque in the hippocampus a) The overall
estimates of hippocampal microglia showed a trend towards transgenic animals having more
microglia present (p=.094), but there was no effect of treatment. b) The number of plaqueadjacent (touching) microglia per plaque did not differ by treatment. c) The number of plaqueproximal (within 30µm) microglia was also not affected by treatment.

Microglia soma size. The size of the somata were then measured and compared across
treatment groups for cells adjacent, proximal, or distant to plaques. This comparison of
microglia soma sizes revealed a significant effect of distance. Microglia that were plaque
adjacent were bigger overall than proximal microglia, which were bigger than distant microglia
(F(2,12)=62.592, p<.001). This finding implies that microglia adjacent to amyloid plaques were
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in an activated, potentially phagocytic, state relative to plaque-distant microglia. When
comparing transgenic animals treated with mFc vs. mIL-1 Trap, there was no overall difference
in microglia size by treatment group (F(2,12)=.29, p=.609). However, there was an interaction
between treatment and proximity (F(2,12)=16.13, p<.001). Animals treated with mIL-1 Trap
had larger plaque-adjacent microglia than those of mFc treated animals. In contrast, the distant
microglia were smaller for the mIL-1 Trap animals (Figure 17). For each transgenic animal, the
average difference in size between plaque-adjacent and plaque-distant microglia was calculated
and used for comparison between animals treated with mFc and mIL-1 Trap. Although all
animals had positive difference scores, indicating larger plaque-adjacent relative to plaquedistant microglia, animals treated with the mIL-1 Trap showed significantly bigger differences in
microglial size than animals treated with mFc (t(6)=4.865, p=.003) (Figure 16).

A. mFc

B. mIL-1 Trap

Figure 16. Representative staining of microglia with Iba-1 (purple) around amyloid
plaques counterstained with Congo Red (red). Scale bar (yellow) = 50µm.
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Figure 17. Average area of microglia by distance to amyloid plaques for each treatment
group. Overall, there was a significant main effect of proximity with plaque-adjacent microglia
having the largest somas and plaque-distant microglia having the smallest. There was a
significant treatment by proximity interaction such that mIL-1 Trap animals had larger plaqueadjacent soma but smaller plaque-distant soma relative to mFc animals. Symbols: main effect of
proximity ***p<.001, interaction shown as ### p<.001).

In order to provide a frame of reference, average microglia soma size was obtained for
wild type mice treated with mFc. We found that transgenic animals in both treatment groups had
larger plaque-distant microglia than the reference group. Therefore, although treatment with the
mIL-1 Trap differentially affected microglial morphology in the hippocampus for the transgenic
animals, hippocampal microglia in these animals were still more activated than in wild type
animals. (Figure 18)
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Figure 18. Comparison of plaque-distant microglia in transgenic mice to wild type mice
treated with mFc. Plaque-distant microglia in transgenic mice of both treatment groups are
larger than hippocampal microglia in wild type mice.

Additional analyses were conducted in order to evaluate microglia soma size in three
areas of the hippocampus (CA1, CA3, and DG). Microglia in all three hippocampal regions
showed the same effect of proximity to plaques with plaque-adjacent microglia having the
largest somas and plaque-distant having the smallest (CA1: F(1,12)=36.089, p<.001; CA3:
F(1,12)=21.711, p<.001; DG: F(1,12)=12.572, p=.001). Regarding the interaction between
treatment and proximity, all three regions appear to show a similar pattern. However, this
interaction is only significant in CA1 (F(1,12)=12.720, p=.001), shows a trend toward statistical
significance in the DG (F(1,12)=3.556, p=.061) and is non-significant in CA3 (F(1,12)=.951,
p=.414). There was no significant main effect of treatment on soma size in any of these
hippocampal areas.

Hippocampal volume. Hippocampal volume was also measured using the Cavalieri
probe. Results of the hippocampal volume analysis did not reveal any differences between
transgenic and wild type animals (F(1,13)=.236, p=.635). Treatment with mIL-1 Trap did not
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affect hippocampal volume (F(1,13)=.800, p=.387) and there was no interaction between
genotype and treatment (F(1,13)=.015, p=903) (Figure 19).
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Figure 19. Estimated hippocampal volume. Estimated hippocampal volume did not differ
between groups

Interim Discussion
Although we found a trend towards more microglia in the hippocampus for transgenic
animals, possibly reflecting greater immune activation associated with the disease state,
microglial density was not affected by chronic IL-1 inhibition with the mIL-1 Trap. These
results are consistent with a recent study that found that i.c.v. administration of IL-1ra did not
affect microglial density in the dentate gyrus (Ben Menachem-Zidon, Ben Menahem, Ben Hur,
& Yirmiya, 2014). However, that study did demonstrate a significant reduction of the number of
microglia associated with or touching amyloid plaques in IL-1ra treated mice. We expected that
administration of the mIL-1 Trap might also significantly reduce the number of plaque-adjacent
microglia in the hippocampus but this was not the case. Despite the lack of effect of IL-1
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inhibition on number of microglia, there were differences seen in the sizes of the somata between
the treatment groups. Specifically, mIL-1 Trap-treated animals had larger plaque-adjacent
microglia than mFc-treated animals, but smaller plaque distant microglia.
It might seem counterintuitive that microglia that were adjacent to plaques were actually
bigger in trap treated animals than mFc treated animals. Since the somata enlarge as microglia
go from a quiescent or ramified state to a more activated state, and IL-1 is known to activate
microglia, one might assume that inhibiting IL-1 would lead to smaller somata. Perhaps the key
finding is the difference in size between microglia that were physically touching plaques and
microglia that are distant from plaques. Although there was an overall effect of plaque distance
on soma size across all transgenic animals, indicating that microglia recruited to the site of the
plaques were in a more activated state, mIL-1Trap-treated animals showed a significantly greater
size difference between these plaque-adjacent and plaque-distant microglia compared to mFctreated animals. Perhaps treatment with mIL-1 Trap resulted in microglia that were less active
overall but that more efficiently responded to the amyloid plaques. In contrast, the microglia of
mice treated with mFc were more reactive in general, but not as responsive to plaques.
The question remains of whether these differences in microglia size are related to
behavioral performances and, if so, by what underlying mechanism. The larger size of the
plaque-adjacent microglia in Trap-treated animals in this study might indicate a shift to an M2
activation state, which is generally anti-inflammatory, pro-neurotrophic, and phagocytic
(Medeiros et al., 2013). However, if the larger microglia represent a more phagocytic
phenotype, one would expect the number of amyloid plaques in the brain to decrease as the
microglia clear the amyloid from the brain. As we previously showed, the plaque burden was
unaffected by treatment with mIL-1 trap, despite the differences in microglia. It is possible that
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microglia in mIL-1 Trap-treated animals are clearing plaques faster, but are also depositing
amyloid faster due to other effects of the drug, resulting in no net difference in plaque burden.
Depending on the study, IL-1 signaling has been shown to either interfere with microgliamediated plaque clearance (Heneka et al., 2010) or facilitate it (Shaftel et al., 2007b), but
reductions in plaque burden on its own has not consistently been accompanied by cognitive
improvements and vice versa. In fact, a study by Kitazawa et al. (2011) that found that inhibiting
IL-1 signaling in 3xTG-AD mice improved water maze performance and led to an increase in
phagocytic activation, as measured by YM-1 and arginase-1, but had only a minimal effect on
amyloid plaque burden. The results of the present study are consistent with these past findings
and suggest that improvements in learning and memory performance are not directly caused by
phagocytosis and clearance of amyloid plaques.
Perhaps the activated microglia in the Trap-treated animals are unable to clear the
amyloid more efficiently, but are still beneficial due to other effects of an M2 phenotype. For
example, a recent study showed that administration of IL-1ra to transgenic mice increased cell
expression of BDNF and rescued hippocampal neurogenesis impairments, along with its
beneficial effects on memory performance (Ben Menachem-Zidon et al., 2014). It may be that
the IL-1 Trap in this study is improving cognition by impacting neurons, via secretion of growth
factors like BDNF or promotion of neurogenesis. In addition, the Trap could be disrupting the
pro-inflammatory IL-1-mediated cascade, inhibiting other pro-inflammatory cytokines and
sparking release of anti-inflammatory substances, which could lead to a variety of downstream
effects. More research will be needed with the mIL-1 trap in order to fully answer these
questions, including staining for markers of M1 vs. M2 activation, BDNF, markers of
neurogenesis, and other pro- or anti-inflammatory substances.
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Chapter 6
CORRELATIONS BETWEEN BEHAVIOR AND ANATOMY

The final step of the study was to analyze the relationship between the behavioral and
anatomical measures in these animals to determine whether changes in amyloid plaque pathology
or microglial characteristics were predictive of changes in ability to learn.

Methods
A regression analysis was performed using quantitative measures of amyloid plaque
burden (total plaque area, plaque number, plaque size) and measures of learning (water maze
acquisition average latency) and memory (water maze retention proportion of time in goal
quadrant and platform crossings). In addition, measures of microglial number and size were also
correlated with these water maze measures, but only for the second cohort due to the
unavailability of microglial values from cohort 1. The analyses were conducted first with all
transgenic animals. The analyses were then conducted separately for transgenic animals treated
with mFc and for animals treated with mIL-1 Trap to determine if the correlations differed
between the groups, suggesting a dissociation of the relationships when IL-1 is inhibited.
Because there was a significant difference in overall plaque burden in transgenic animals
from cohort 1 to cohort 2 (with cohort 1 showing more plaque pathology), but no interaction of
cohort with treatment, a z transformation was conducted for the plaque burden values in order to
better assess the relationships between amyloid burden and other measures for the two cohorts
combined. Values for total plaque proportion, plaque number, and plaque size for each animal
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were converted into z scores using the means and standard deviations for each animal’s treatment
group and cohort. These z scores were then used to correlate with other measures.

Results
Plaque burden vs. water maze measurements. The correlation analyses revealed a
significant negative relationship between average latency on water maze acquisition and the
number of platform crosses on water maze retention (r(16)=-.494, p=.037), such that animals that
performed worse on the acquisition phase (took longer to find the platform) tended to perform
worse on the retention portion (made fewer platform crosses). In contrast, the average latency to
find the platform did not correlate significantly with proportion of time spent in the goal
quadrant during retention. In addition, the proportion of plaques in the hippocampus correlated
significantly with plaque count (r(16)=.819, p<.001), such that having a higher number of
plaques was related to a higher overall proportion of the hippocampus covered by plaques.
There were no significant correlations between any of the plaque measurements (proportion,
count, or average size) and any of the cognitive measures on water maze acquisition or retention
(see Table 2).
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Table 2. Correlations between plaque burden and water maze measurements for all
transgenic animals
WM Aquis
(average
latency)
--

WM
latency
WM – prop -.194
goal
WM – plat -.494*
cross
Plaque
.422
prop z
Plaque
.166
count z
Plaque size .179
z
Notes. *p<.05, **p<.01

WM Retent
(prop in
goal)
-.194

WM Retent
(platform
crosses)
-.494*

Plaque
Proportion
z
.422

Plaque
Count z

Plaque size
z

.166

.179

--

.129

-.334

-.049

-.422

.129

--

-.262

-.324

.121

-.334

-.262

--

.819**

-.033

-.049

-.324

.819**

--

-.416

-.422

.121

-.033

-.416

--

Next, the correlations were performed separately for transgenic mice treated with mFc
and transgenic mice treated with mIL-1 Trap (see tables 3 and 4). The mFc mice had a
significant positive correlation between average latency on water maze acquisition and plaque
proportion, (r(7)=.673, p=.047), such that higher overall plaque burden corresponded to longer
latencies to escape the platform during the acquisition phase. However, when looking at only
animals treated with mIL-1 Trap, there was no longer any significant correlation between water
maze acquisition and plaque proportion (r(7)= .268, p=.485) (Figure 20).
Similar to the results for all transgenic animals combined, those treated with mFc showed
a strong negative correlation between water maze acquisition and platform crosses on the
retention portion with worse performance on acquisition correlating with fewer platform crosses
on retention. Again, there was no significant relationship between acquisition and the proportion
of time spent in the goal quadrant in retention. In contrast, there was no correlation between
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water maze acquisition and either of the retention variables for mIL-1 Trap-treated animals
alone.
The proportion of hippocampus covered by plaque was positively correlated with the
number of plaques in both mFc (r(7)=.938, p<.001) and mIL-1 Trap (r(7)=.700, p=.036) animals.
For mFc animals alone, plaque size and count were significantly negatively related (r(7)=-.735,
p=.024), such that the more plaques were present, the smaller they were. However, no such
relationship was found in the mIL-1 Trap animals (r(7)=-.097, p=.803).

Table 3: Correlations between plaque burden and water maze measurements for
transgenic – mFC animals
WM Avg
Lat

WM prop
goal

-.107
Water Maze -Avg latency
-.107
-WM prop
ingoal quad
-.874**
.251
WM plat.
cross
-.104
Plaque prop. .673*
(z)
.490
.111
Plaque
count (z)
.080
-.430
Plaque size
(z)
Notes. *p<.05, **p<.01, ***p<.001

WM plat
cross

Plaque
Prop z

Plaque
Count z

Plaque size
z

-.874**

.673*

.490

.080

.251

-.104

.111

-.430

--

-.443

-.214

-.314

-.443

--

.938***

-.461

-.214

.938***

--

-.735*

-.314

-.461

-.735*

--
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Table 4: Correlations between plaque burden and water maze measurements for
transgenic-mIL-1 Trap animals
WM Aquis
(average
latency)
-WM
latency
WM – prop -.291
goal
WM – plat -.281
cross
.268
Plaque
prop (z)
-.129
Plaque
count (z)
Plaque size .326
(z)
Notes. *p<.05

WM Retent
(prop in
goal)

WM Retent
(platform
crosses)

Plaque
Proportion
z

Plaque
Count z

Plaque size
z

-.291

-.281

.268

-.129

.326

--

.024

-.610

-.239

-.416

.024

--

-.135

-.412

.443

-.610

-.135

--

.700*

.394

-.239

-.412

.700*

--

-.097

-.416

.443

.394

-.097

--

Plaque proportion (z) vs. average WM latency
Average latency to escape to platform
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Figure 20. Plaque proportion (z score) vs. average water maze latency for each treatment
group. For transgenic animals treated with mFc, a greater proportion of the hippocampus
covered by amyloid plaque was significantly correlated with longer latencies to escape to the
platform in water maze acquisition. There was no significant relationship between the two
variables for the transgenic animals treated with mIL-1 Trap.
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Microglia vs. water maze measurements. A regression analysis was conducted
including the three water maze measures as well as measures of microglia size and activation
(average number of adjacent microglia per plaque, size of microglia adjacent to, proximal to, and
distant from plaques, and the difference in size between the adjacent and distant microglia).
There was a significant positive correlation between size of plaque-proximal microglia and the
number of platform crosses on water maze retention (r(6)=.747, p=.033). However, none of the
other microglial measures correlated with any of the cognitive measures.

Table 5: Correlations between measures of microglia number and size and water maze
measurements for all transgenic animals

Water Maze
Avg Latency
WM Prop in
goal Quad
WM plat.
crosses
Microglia #
plaq-adjacent
Microglia #
prox
Microglia
Size adjacent
Microglia
Size proximal
Microglia
size distant

WM
Avg
Lat.
--

WM
prop
goal
-.194

WM
Plat Cr

Micro
# Adj

Micro
# Prox

micro
size Adj

Micro
size Dist

-.223

Micro
size
Prox
-.062

-.494*

-.108

-.059

-.194

--

.129

-.267

.108

-.266

-.095

-.043

-.494*

.129

--

-.372

.402

-.324

.747*

.333

-.108

-.267

-.372

--

.464

.472

.228

.282

-.059

.108

.402

.464

--

-.119

.571

.603

-.223

-.266

-.324

.472

-.119

--

-.038

-.606

-.062

-.095

.747*

.228

.571

-.038

--

.556

.240

-.043

.333

.282

.603

-.606

.556

--

.240

Notes. *p<.05, **p<.01, ***p<.001

When looking at each treatment group separately, different patterns of relationship
between learning & memory and microglial parameters emerged. For mFc animals alone, the
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size of plaque-distant microglia was negatively correlated with water maze retention platform
crosses (r(2)=-.954, p= .046), such that the larger the microglia, the fewer platform crosses they
made. Not only did mIL-1 Trap treated animals not show the same pattern, the relationship
between size of distant microglia and platform crosses was actually positive (r=.891), although it
did not reach significance (p=.109) Figure 21b). In addition, mIL-1 Trap treated animals showed
a significant relationship between the average number of plaque-adjacent microglia and
proportion of time spent in the goal quadrant during water maze retention (r(2)=.955, p=.045),
indicating that more microglia around plaques corresponded to better performance on this aspect
of water maze retention. mFc-treated animals seemed to show the opposite pattern (r=-.847), but
the relationship was not significant (p=.153) (Figure 21a).
A look at the correlations between average soma sizes of microglia that were adjacent,
proximal, and distant to plaques also revealed a difference between treatment groups. For mFc
animals, the size of plaque-proximal microglia positively correlated with the size of plaqueadjacent microglia (r(2)=.957, p=.043), but not to plaque distant microglia (r(2)=-.199, p=.801).
For mIL-1 Trap animals, though, the plaque-proximal microglia size correlated significantly to
the plaque-distant size (r(2)=.957, p=.043), but not to plaque-adjacent microglia (r(2)=.099,
p=.901). In other words, the size of microglia that were near plaques was more similar to
plaque-adjacent microglia for mFc animals, but more similar to plaque-distant microglia for
mIL-1 Trap animals. This finding may support the idea that microglial activation was more
targeted to plaques in mIL-1 Trap animals but more generally reactive in mFc animals.
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Table 6. Correlations between measures of microglia number and size and water maze
measurements for transgenic animals treated with mFc

Water
Maze Avg
Latency
WM Prop
in goal
Quad
WM plat.
crosses
Microglia
# adjacent
Microglia
# near
Microglia
Size
adjacent
Microglia
Size
proximal
Microglia
size
distant

WM
Avg
Lat.

WM prop
goal

WM
Plat Cr

--

-.107

-.107

Micro#
Prox

micro
size
Adj

Micro
size
Prox

Micro
size Dist

-.874** .898

.368

.046

-.177

.619

--

.251

-.847

-.904

-.686

-.624

-.558

-.878**

.251

--

-.831

-.076

.304

.370

-.954*

.898

-.847

-.831

--

.598

.256

.121

.792

.368

-.904

-.076

.598

--

.927

.850

.150

.046

-.686

.304

.256

.927

--

.957*

-.210

-.177

-.624

.370

.121

.850

.957*

--

-.199

.619

-.558

-.954*

.792

.150

-.210

-.199

--

Notes. *p<.05, **p<.01,

Micro
# Adj
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Table 7. Correlations between measures of microglia number and size and water maze
measurements for transgenic animals treated with mIL-1 Trap

Water
Maze Avg
Latency
WM Prop
in goal
Quad
WM plat.
crosses
Microglia
# adjacent
Microglia
# proximal
Microglia
Size
adjacent
Microglia
Size
proximal
Microglia
size
distant

WM
Avg
Lat.

WM
prop
goal

WM
Plat Cr

Micro
# Adj

Micro#
Prox

micro
size
Adj

Micro
size
Prox

Micro
size
Dist

--

-.291

-.281

-.679

-.308

.097

-.110

-.202

-.291

--

.024

.955*

.791

.467

.296

.505

-.281

.024

--

.350

.440

.222

.938

.891

-.679

.955*

.350

--

.893

.545

.540

.731

-.308

.791

.440

.893

--

.850

.478

.711

.097

.467

.222

.545

.850

--

.099

.354

-.110

.296

.938

.540

.478

.099

--

.957*

-.202

.505

.891

.731

.711

.354

.957*

--

Note. *p<.05,
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Figure 21. Correlations of size/number of microglia vs. water maze retention for both
treatment groups. A) mIL-1 Trap-treated animals showed a significant positive correlation
between the average number of plaque-adjacent microglia and proportion of time spent in the
goal quadrant in water maze retention. In contrast, mFc-treated animals showed a negative,
though nonsignificant, relationship. B) For mFc-treated animals, the size of plaque-distant
microglia was significantly negatively correlated with number of platform crosses. However,
mIL-1 Trap-treated animals showed a positive relationship between these variables.
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Interim Discussion
To evaluate the role of amyloid plaques in cognition, we looked at the relationship
between plaque deposits and water maze performance for transgenic animals. Blessed et al.
(1968) first reported a correlation between the number of senile plaques in the neocortex and
cognitive performance in Alzheimer’s patients. Since then, positron emission tomography (PET)
using Pittsburgh Compund-B (PIB) has allowed researchers to more closely examine the
relationship between AD and amyloid plaques in vivo (Klunk et al., 2004), but studies looking at
the relationship between Aβ load and cognitive function have generally found either a weak
correlation (Villemange et al., 2011) or no correlation (Edison et al., 2008; Yokokura et al.,
2011). In the present study, when looking only at transgenic animals treated with mFc, we did
find a significant correlation between water maze acquisition and plaque burden, with higher
proportion of plaques in the hippocampus correlating with poorer performance (longer latencies
to find platform). However, transgenic animals treated with mIL-1 Trap showed no significant
relationship between these variables. As demonstrated in chapter 4, treatment with mIL-1 Trap
did not alter the overall plaque burden, but here we have showed that it eliminated the significant
relationship between those plaques and learning performance. This dissociation between
cognitive function and plaque burden supports the hypothesis that it is the immune response to
the plaques, rather than the plaques themselves, that are causing the cognitive impairments.
In order to assess the relationship between immune activation and cognitive performance,
we then correlated our various microglia measurements with the same water maze measures.
Unfortunately, these correlations could only be conducted with the second cohort, as microglia
data from the first cohort were unavailable. Nonetheless, there were some interesting patterns
that emerged. For animals treated with the mIL-1 Trap, higher numbers of plaque-adjacent
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microglia corresponded significantly to more time spent in the goal quadrant during water maze
retention whereas the opposite pattern was seen in animals treated with mFc. Also, the mFc
animals showed a significant negative relationship between size of plaque-distant microglia and
number of platform crosses with the opposite pattern in mIL-1 Trap animals. Taken together,
these correlations seem to show a pattern where the presence of microglia and the size of the
somata relate to negative memory performance in mFc animals but improved memory
performance in mIL-1 Trap animals. It is interesting that these correlations are seen with water
maze retention measures, since performance on these measures did not differ between the
treatment groups overall (see Chapter 3). It appears as though treatment with mIL-1 Trap may
have shifted the relationship between microglial activation and memory, without improving
performance overall.
In addition, although most of the correlations between the cognitive measures and
microglia measures are not significant for either the mFc or mIL-1 Trap groups, likely due to
very small sample sizes, the pattern of correlations appears to be generally different between the
two groups. The animals treated with mIL-1 Trap show all positive (although mostly
nonsignificant) correlations between measures of microglial size/number and measures of water
maze retention. In contrast, animals treated with mFc had mostly negative correlations between
the same variables. A similar pattern can be seen in correlations between water maze latency
and microglial measures, such as number of plaque-adjacent microglia, with mIL-1 Trap animals
tending to show negative correlations (e.g. more microglia associated with faster latencies), but
mFc animals showing positive correlations. These patterns are interesting and may warrant
further study, but none of those measures reach statistical significance and thus, no conclusions
can be drawn at this point.
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Another consideration that must be mentioned is the question of whether administering
mFc alone has any behavioral effects on these animals. mFc was chosen as a control as it is a
component of the mIL-1 Trap but does not contain the IL-1 inhibiting properties. It is assumed
that it has no significant effects on biology or behavior, but in order to definitively answer that
question, a true treatment-naïve control group would be necessary. The correlations shown with
the mFc group alone could potentially reflect subtle effects of chronic mFc administration.
These findings suggest that, although measures of microglial density and the number of
microglia around plaques are not affected by mIL-1 Trap treatment, the presence of microglia is
more beneficial after IL-1 Trap treatment. This relationship could suggest that the mIL-1 Trap
shifts the microglia to an alternative activation phenotype that is generally more beneficial for
hippocampal function. It is, however, still not clear whether the relationship shift toward
microglia being more beneficial is due to more effective phagocytosis of amyloid (unlikely since
plaque burden is unaffected), due to other aspects such as secretion of BDNF, or due to some asyet unexplained effect. More research will be necessary in order to determine the exact nature of
the relationship between microglia and cognitive functioning.
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Chapter 7
DISCUSSION
In this study, we used systemic administration of the mIL-1 Trap to inhibit interleukin-1
signaling for 5 months after the onset of disease in order to observe its effects on both behavior
and Alzheimer’s-like brain pathology. Our initial hypothesis was that IL-1 inhibition would
improve performance on measures of learning and memory while reducing plaque burden. We
found that animals treated with the mIL-1 Trap performed significantly better on a spatial
learning task (water maze acquisition) although there was no difference on retention. However,
treatment with the Trap had no effect on amyloid plaque burden in the hippocampus. We then
investigated its effect on the immune response by analyzing hippocampal microglia. There was
no difference between treatment groups in either the overall number of microglia in the
hippocampus or the number of microglia adjacent (touching) or proximal (within 30µm) to
amyloid plaques. It did alter the sizes of microglia somata in the hippocampus such that Traptreated animals had larger plaque-adjacent microglia but smaller distal microglia. Finally, we
looked at the relationship between the anatomical measures and performance on behavioral
testing. Treatment with the mIL-1 Trap eliminated the significant positive relationship between
plaque burden and cognitive impairments seen in mFc-treated transgenic mice. None of the
microglial measures (number or soma size) significantly correlated with the behavioral measures.
Our behavioral findings are consistent with previous research showing that inhibiting
inflammation can have a positive effect on cognition in AD. Specifically, He et al. (2011)
showed that transgenic AD rats treated with tetrandine had both reductions of hippocampal IL-1β
and TNFa and improved spatial memory. A recent study directly targeted IL-1 inhibition in TG
mice by using intra-hippocampal transplantation of neural precursor cells overexpressing IL-1ra
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found a complete reversal of memory impairments (Ben Menachem-Zidon et al., 2014). There is
even some support for peripheral IL-1 inhibition improving memory function. Kitazawa et al.
(2011) demonstrated improved water maze performance in aged 3xTg-AD mice after six months
of intraperitoneal injections with IL-1 receptor blocking antibody. Interestingly, only a small
proportion of the peripherally administered anti-IL-1R mAb was detected in the brain, raising
questions of how much of the effects were due to direct CNS action versus peripheral effects of
IL-1 inhibition. The findings of our study add to the story of IL-1’s role in AD. Most previous
studies inhibiting IL-1 in transgenic rodents have used IL-1ra, but ours is the first to use the mIL1 Trap, a more potent blocker of IL-1 action. We also showed an effect using subcutaneous
injections, rather than intraperitoneal or intracerebral administration.
In addition to the behavioral results, we found that IL-1 inhibition had no effect on plaque
burden in the hippocampus. This finding was somewhat surprising because past studies have
implicated IL-1 in APP expression and processing as well as amyloid plaque deposition (Griffin
et al., 1995, Sheng et al., 2003, Goldgaber et al., 1989). However, other recent studies have
showed no reduction in plaque pathology after systemic inhibition of IL-1 in aged transgenic
mice (Kitazawa et al., 2011). Taken together with the water maze data, these results suggest that
other factors are contributing to cognitive deficits seen in Alzheimer’s disease. Although
plaques are the hallmark pathological signs of AD, the relationship between plaques and
cognition is controversial, with more and more researchers concluding that amyloid is not the
main culprit. For example, studies using PIB have not consistently shown any correlation
between plaque burden and performance on cognitive testing. In our study, there was a strong
significant correlation between amount of hippocampal area covered by plaques and
performance on the acquisition phase of the Water Maze, such that animals with worse plaque
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pathology performed worse on the maze. However, in animals treated with the mIL-1 Trap, this
relationship was eliminated. Although the plaques were still present, they were no longer
associated with the animals’ cognitive performance. These findings fit with the growing body of
evidence against the amyloid cascade hypothesis, and suggest that there are factors downstream
of the plaques themselves that are causing the memory impairments in AD.
Because the amyloid pathology had not changed with IL-1 Trap treatment in our studies,
the next step was to examine the immune response to the plaques. We chose to look at microglia
because of the prominence of IL-1β-expressing microglia in the AD brain, especially
surrounding amyloid plaques (Griffin et al., 1989). It is thought that this clustering of microglia
suggests attempts to phagocytose and clear the amyloid deposits. However, these microglia
remain in a classically activated state with impaired phagocytosis and increased expression of
pro-inflammatory cytokines as well as harmful reactive oxygen and nitrogen species (Hickman et
al., 2008; Weldon et al., 1998). In the current study, microglia that were adjacent to amyloid
plaques had significantly larger somata than microglia that were not near plaques, indicating
activation of the plaque-associated cells. However, animals treated with mIL-1 Trap had larger
plaque-adjacent microglia and smaller plaque-distal hippocampal microglia compared to mFc
treated animals. This discrepancy may indicate that Trap-treated animals have more quiescent,
resting microglia in general, but they are more reactive in contact with amyloid. These larger
somata may also indicate a shift to an M2 or alternative activation state. The M2 phenotype is
thought to be more phagocytic, suggesting that the microglia in these Trap-treated animals are
better suited to clear the amyloid plaques. However, this is contradicted by the finding that
amyloid plaque burden was not changed in animals treated with mIL-1 Trap.
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Finally, some correlations were observed between the measures of microglial number and
morphology and certain behavioral measures, which differed between mFc and mIL-1 Traptreated animals. In animals treated with the mIL-1 Trap, having more plaque-adjacent microglia
and larger plaque-distant microglia both corresponded to better performance on water maze
retention, whereas for animals treated with mFc, more plaque-adjacent microglia and larger
plaque-distant microglia were associated with poorer retention performance. These differences
seem to support the idea that the mIL-1 Trap shifted the microglia into an alternative activation
phenotype in which activation is beneficial, rather than detrimental. As mentioned above, the
fact that plaque burden did not decrease suggests that phagocytosis is not the underlying
beneficial mechanism of the microglia, but perhaps the microglia are affecting behavior in other
ways, such as through secretion of growth factors like BDNF. Ultimately, the role of microglia
in AD pathology is still not clear and warrants further study.

Limitations
Although the current study showed a potentially protective role of systemic mIL-1 Trap
treatment in the swAPP/PS-1 double transgenic model of Alzheimer’s Disease, there were a
number of limitations to the study. For instance, this study just looked at one time point in the
course of the Alzheimer’s-like pathology. It is possible that the effects of the drug may differ at
different stages of the disease. In particular, starting the treatment course earlier might have
been more effective in preventing the onset of AD-like symptoms. We chose 8 months as the
starting point for treatment because this is when swAPP/PS1 first consistently show pathological
signs of AD (Hickman et al., 2008) and water maze impairments (Reiserer et al., 2007). In
humans, we can rarely predict the onset of AD before symptoms appear, and therefore we chose
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to start treatment once the disease had started in order to increase clinical relevance in translating
the results from mice to humans.
Another potential limitation of our study was our choice to use systemic, rather than
intracerebral, injections of mIL-1 Trap. This choice might have limited the effectiveness of the
drug, given that the blood brain barrier could have prevented the drug from having its maximum
effect. Although we did see an effect even with these systemic injections, we do not know if the
drug is having its effects peripherally or centrally. If the drug had no measurable effects
whatsoever, this question would become very important. We would need to determine whether
the drug truly is truly not effective in this disease or whether the peripheral administration
prevented it from reaching its target. Because there were significant effects found both in
behavior and pathology, we have shown that the mIL-1 trap can be therapeutic even when given
peripherally. Again, we chose this method of drug administration in order to increase clinical
relevance. If the drug can be effective when injected subcutaneously, it would prove more
promising as a human treatment because of the potential to avoid brain surgery for device
implantation.
Another issue is that small sample sizes and high variability in this study may have
interfered with our ability to detect significant results in some of our measures, particularly our
microglia analyses which could only be conducted with one cohort because of failure of the
tissue to immunostain microglia well in the first cohort. We might have increased the effect size,
thereby partially compensating for the small sample size, if we had used higher or more frequent
doses of the mIL-1 Trap. Previous studies using the same reagent in a mouse model of gout
showed optimal efficacy at 35mg/kg three times a week (Torres et al., 2009). We were,
however, hesitant to use these more aggressive dosing parameters in a 5-month treatment
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regimen in older mice given the potential for chronic mild immunosuppression. Future studies
could, perhaps, probe the impact of higher or more frequent doses, especially given that our
animals appeared grossly healthy.
Finally, the difference in background lineage for the experimental animals between the
first and second cohort is a limitation. These differences in strain add overall variability to the
study and could also account for some of the differences between cohorts. However the effect of
treatment did not interact with any other variable for any measure such that the effects of the
mIL-1 Trap were the same regardless of the background strain. Particularly, the fact that
treatment with mIL-1 Trap had a similar effect on water maze performance for both cohorts is
encouraging. Ideally the results should be repeated with mice from the same lineage to more
fully elucidate the effects of Il-1 inhibition on behavior without the potential complication of
background strain.

Future Directions
The findings presented here raise several questions and suggest directions for future
research. One potential avenue for investigation is to more fully explore the effects of IL-1
inhibition on the immune response. The present study used an Iba-1 stain to look at microglia
density and basic morphology. However, future studies should differentiate between classic
(M1) and alternative (M2) microglia activation profiles. It is possible that the change in soma
size of plaque-adjacent microglia in animals treated with mIL-1 Trap compared to mFc
represents different activation phenotypes, but more targeted immunostaining with M1
associated markers such as iNOS, MHCII or TNFa and M2-associated markers like arginase or
IL-10 would be needed to answer that question (Varnum and Ikezu, 2012).
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The distinction between resident microglia and infiltrating peripheral macrophages has
also been addressed in recent research studies. For example, Stalder et al. (2005) used green
fluorescent protein to demonstrate that peripheral bone marrow-derived macrophages invade the
CNS and surround amyloid plaques in transgenic APP23 mice. Since macrophages take on
different activation phenotypes similar to what is seen in microglia, some have hypothesized that
these invading peripheral cells are driving the difference between classical and alternative
activation in the CNS (Ransohoff and Brown, 2012). Perhaps future studies with the mIL-1 Trap
in AD could use similar GFP-labeling methods to differentiate between resident and peripheral
cells.
In addition to immune cells, future studies should investigate the effects of the mIL-1
Trap on other markers of plasticity. A recent study demonstrated that impaired hippocampal
neurogenesis in transgenic AD animals can be completely rescued by implantation with neural
precursor cells expressing Il-1ra and partially reversed with intracerebroventricular IL-1ra
administration (Ben Menachem-Zidon et al., 2014). This study also demonstrated a significant
increase in endogenous hippocampal cells expressing the growth factor BDNF. Since IL-1
suppresses BDNF expression in the hippocampus (Barrientos et al, 2004), inhibiting IL-1 with
the mIL-1 Trap might have increased hippocampal BDNF levels therefore promoting functional
recovery. Finally, it may be important to examine the effect of IL-1 inhibition on synapses in the
hippocampus and cerebral cortex. Synapse loss, as measured by reduced synaptophysin
immunoreactivity, is seen in AD brains but has been shown to correlate with markers of
inflammation, rather than with Aβ load (Lue et al., 1996). In fact, these markers of synapse loss
and inflammation differentiated between AD patients and high pathology controls who exhibited
amyloid plaques and neurofibrillary tangles but did not show overt dementia.
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Another potential goal for future research is to determine the exact pathways by which
peripheral inhibition of IL-1 can affect brain pathology and behavioral changes in AD animals.
One possibility is that the trap is crossing over the blood brain barrier and directly inhibiting IL-1
expression in the brain. This explanation is unlikely since the Trap is a relatively large
biological protein and can probably only cross the BBB in very small amounts. One way to
address that question could be to stain for mFc in the brain, which should be relatively low in
normal animals. Alternatively, one could measure IL-1 levels or mIL-1 Trap levels in the brain
using assays, which could not be conducted in perfusion fixed tissue. Even if the Trap itself does
not enter the brain, it could affect CNS indirectly through the peripheral nervous system. There
are a number of pathways by which peripheral expression of IL-1 can induce expression in the
brain, which explain how peripheral infections can induce sickness-related behaviors and altered
cognition. Through the neural pathway, peripheral pathogens and cytokines stimulate primary
afferent nerves which project to the nucleus tractus solitarius and then to structures of the
hypothalamus, extended amygdala, and the periaqueductal grey (Dantzer et al., 2008).
Alternatively, circulating PAMPs can activate the humoral pathway through the choroid plexus
and circumventricular organs, inducing production of pro-inflammatory cytokines, which then
enter the brain by volume diffusion (Dantzer et al., 2008). Systemic administration of mIL-1
Trap could be impacting brain expression of IL-1 through one of these pathways. Finally, as
mentioned before, IL-1 inhibition in the periphery could be altering activation of peripheral
monocytes and macrophages affecting their recruitment to the CNS in response to plaque
deposition. Further studies would need to be conducted in order to determine the exact method
by which the mIL-1 Trap is impacting brain pathology and ultimately behavior.
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Another way to explore the role of cytokines in AD is to use genetic methods of blocking
IL-1, rather than pharmacological interventions. Our lab previously attempted to cross swAPPPS1 mice with IL-1R1 knockout mice, which lack the main endogenous interleukin-1 receptor,
in order to evaluate how a lack of interleukin signaling affected the disease progression.
Although our attempts at breeding these two strains resulted in poor viability in the offspring,
this could be a potential avenue for future research.
Finally, it would be interesting to track learning and memory over time in these animals
using repeated behavioral testing. This sort of study could establish a timeline of cognitive
decline and would be useful for targeting treatment to the point when cognitive impairments first
appear. In addition, other measures of memory should be used in order to tease out why animals
showed improved learning on water maze acquisition, but not retention. Perhaps using other
hippocampal tasks in addition could help determine whether this water maze pattern reflects
different strategies used by the mice or whether there is truly no effect on memory retention.

Impact
This study has potential implications for the understanding and treatment of Alzheimer’s
Disease. First, the current study provides support for the growing hypothesis that amyloid
plaques do not, themselves, cause the hallmark cognitive impairments of Alzheimer’s Disease.
Indeed, it supports the idea that components of neuroinflammation, perhaps triggered in part by
the presence of the plaques, are major pathogenic contributors. Finally, our data provide initial
evidence that the IL-1 Trap could be a promising treatment for AD related cognitive
impairments. The findings suggest that even large biological inhibitors of IL-1, given after
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disease onset, could provide significant benefit to patients suffering from the profound cognitive
impairments characterizing this devastating disease.
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